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ABSTRACT 
Background: Prostate cancer is one of the top diseases that are killing men world over and is 
the second common cancer that affects men.   According to the 2012 Globocan statistics, 
approximately 1.1 million males were found to have prostate cancer globally, which was 
found to be at 15% compared to other cancers seen in males. The incidence and mortality 
rate of the disease in the Southern African Development Community region is 40.5 per 100 
000 and 22.5 per 100 000 of the population per year, respectively. However, the National 
Cancer Registry of South Africa (2012) has indicated that in South Africa, 31.36 per 100,000 
men were found to have this cancer. 
Aim: The study aimed to describe the knowledge, attitudes and practices of men living in 
Muldersdrift, South Africa, concerning prostate cancer.  
Method: The setting was Ward 23, commonly known as Video, a resource poor area, in 
Muldersdrift. A door-to-door survey was conducted. The convenience sampling method was 
used on a sample size of n=183. Data were collected by means of structured interviews and 
a questionnaire served as the data collection instrument. The data were analysed by means 
of descriptive statistics and the Fisher’s Exact Test was used to calculate statistical 
significant differences between the variables. 
Results: The sample (n=183) about half were above the age of 70 years (48.1%; n=88), 
mean  52.4, SD ±9.5 and median 50.Over a third of respondents were from the Tswana 
cultural group (36.6%; n=67) and the highest percentage never went to school (30.1%; 
n=55).The majority of respondents (90.2%; n=165) had never heard of prostate cancer and 
only 9.8% (n=18) had ever heard of the disease. When calculating the overall knowledge 
about prostate cancer, all respondents (n=183) scored between 0 and 49% (equates with 
low).The majority of the respondents (72.0%; n=132) had a positive attitude towards prostate 
cancer. Out of the 10 answers considered to be positive practices, approximately two-thirds 
of the respondents (60.7%; n=111) responded positively to two questions only. 
Conclusion: The study provided evidence that the men living in the study setting had limited 
knowledge of prostate cancer. However, they presented with a positive attitude regarding 
prostate cancer, and high percentages were ready to perform prostate cancer screening and 
to learn about the disease. 
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CHAPTER ONE 
OVERVIEW FOR THE STUDY 
1.1 INTRODUCTION 
This chapter provides an overview for the study. Prostate cancer is introduced and the 
research question, aim and significance of the study are described. In addition, a brief 
description is given of the methods and design utilised in this research. 
1.2 BACKGROUND 
Prostate cancer is one of the top diseases killing men world over and is the second common 
cancer that affects men (Mofolo et al., 2015). According to the 2012 Globocan statistics 
(WHO, 2012), approximately 1.1 million males were found to have prostate cancer globally, 
which was found to be at 15% compared to other cancers seen in males.  Although 70% of 
men newly diagnosed lived in more developed regions, Africa has 52 000 men who were 
found to have confirmed cases of prostate cancer. This disease is commonly found in Blacks 
and Mixed Race males than in males of Western regions (Ogundele and Ikuerowo, 2015).  
According to Kangmennaang et al. (2016), the relatively lower trends in Sub-Saharan Africa 
understate the true magnitude of the disease due to the low detection rate. Many men go 
undiagnosed due to a lack of knowledge, diagnostic facilities, trained health personnel and 
screening, such as the Prostate Specific Antigen (PSA). 
The incidence and mortality rate of the disease in the Southern African Development 
Community region is 40.5 per 100 000 and 22.5 per 100 000 of the population per year, 
respectively (Mofolo et al., 2015). However, the National Cancer Registry of South Africa 
(2012), has indicated that the incidence rate of prostate cancer among men in South Africa 
is 31.36 per 100 000 (NHLS, 2012). The South African National Cancer Registry (2010), 
recorded 4652 incidences of prostate cancer, which were histologically diagnosed in South 
Africa during 2010 (CANSA, 2016). White males were highly affected with 2864 incidences, 
followed by Black males with 2448 incidences, Coloured males with 702 and Asian males 
with 125  (CANSA, 2016). 
According to So et al. (2014), the things that give rise to the occurrence of prostate cancer 
are not well known. It is however believed that risk factors such as advanced age, having a 
family history of prostate cancer and being a member of black ethnic group can contribute to 
this disease. In addition, prostate cancer is caused by a number of factors and both genetic 
and environmental/lifestyle factors contribute to its development. Ogundele and Ikuerowo 
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(2015) indicate that diet and lifestyle monitoring has shown to reduce the risk of prostate 
cancer development. 
The screening methods utilised to test for prostate cancer in males who are asymptomatic 
are Prostate Specific Antigen (PSA) and a Digital Rectal Examination (DRE). Men are 
counselled prior to undergo these tests (Nakandi et al., 2013). These tests should be 
conducted in men who shows signs and symptoms of prostate cancer, or in men who 
consent to be tested for this disease (Horwich et al., 2010). The Prostate Cancer Foundation 
of South Africa (PCFSA, 2013) supports both tests and recommends that Black South 
African men, with a family history of prostate cancer, be screened from the age of 40 years 
and all other men from 45 years onwards. In South Africa, screening for prostate cancer is 
done in an opportunistic manner and not on a population-based manner. However, 
opportunistic screening has limitations because not all men are covered. 
Prostate cancer has various symptoms, which include blood in the urine, urinating frequently 
especially during the night, delayed or prolonged urination, weak urine stream, incomplete 
emptying of the bladder, pain when passing urine, change in bowel habits, difficulty to start 
urinating, blood in the urine and new onset of erectile dysfunction. When prostate cancer is 
advanced, men may experience bone pain, often in the spine or pelvis, leg weakness and 
urinary incontinence if cancer has spread to the spine and compressed the spinal cord. 
Furthermore, the Prostate Cancer Foundation of South Africa (PCFSA, 2013) indicates that 
some men may experience painful ejaculation. Factors such as embarrassment, lack of 
knowledge, being asymptomatic and financial status contribute to late detection of prostate 
cancer(So et al., 2014). When prostate cancer is detected late the survival rate is low 
(Kabore et al., 2014).  
1.3 RESEARCH PROBLEM 
The research problem for this study focused on prostate cancer, specifically the knowledge, 
attitudes and practices pertaining to this disease. This disease is seen more often in South 
African men and the incidence rate of the disease is escalating in all men (NHLS, 2012). 
According to Kabore et al. (2014) and Nakandi et al. (2013), prostate cancer is detected at a 
more advanced stage in men living in Africa as they have limited knowledge and many hold 
myths concerning the disease and early detection services. Moreover, the lack of population-
based screening in South Africa aggravates the problem. 
 
Little is known about the knowledge, attitudes and practices of men relating to prostate 
cancer, as no South African study seems to be available investigating all these factors. 
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Studies conducted in South Africa, which focused primarily on knowledge, found that men 
have limited knowledge concerning prostate cancer (Mofolo et al., 2015, Matshela et al., 
2014), whilst attitudes and practices of men in terms of prostate cancer itself and screening 
for this disease does not seem to have been investigated. With this study, the researcher 
wishes to provide baseline data to address the knowledge gap. 
1.4 RESEARCH QUESTION 
The research question for this study was:  
What are the knowledge, attitudes and practices of men living in Muldersdrift, South Africa, 
concerning prostate cancer?  
1.5 AIM OF THE STUDY 
The study aimed to describe the knowledge, attitudes and practices of men living in 
Muldersdrift, South Africa, concerning prostate cancer. 
1.6 SIGNIFICANCE OF THE STUDY 
The significance of the study pertains to the little information available about the knowledge, 
attitudes and practices of men concerning prostate cancer in South Africa. The prevention of 
diseases is a national priority for improving patient care (Mofolo et al., 2015),therefore, the 
findings of the study could provide important information that could be used for planning 
preventive campaigns.  
1.7 SETTING AND METHODS 
More details about the setting and methods will be presented later in the report. The setting 
was Ward 23, commonly known as Video, a resource poor area, in Muldersdrift. The 
population consisted of all men which are 40 years and older. According to South African 
profile database(Frith, 2011), Ward 23 has 436 males. The Raosoft sample size calculator 
was used to calculate the sample size: population n=436, margin error 5%, confidence level 
of 95% gave a sample size of n=183, and convenience sampling, which involves using 
participants who happen to be in the right place at the right time (Grove et al. (2013), was 
used to select the sample. A door-to-door survey was conducted and data were collected by 
means of structured interviews, and a questionnaire served as the data collection 
instrument. The data were entered into an Excel spreadsheet and analysed by means of 
STATA version 15.0 computer programme. Data were analysed using descriptive statistics 
and Fisher’s Exact Test. 
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  The Fishers Exact Test was used to determine the association between variables with the 
significance level set at 0.05 (p=0.05) (Greenland et al., 2016). 
1.8 OPERATIONAL DEFINITIONS 
Prostate: is a reproductive system organ that is found directly under the urinary bladder, in 
front of the rectum. It is almost the size of a walnut (PCFSA, 2013). 
 
Prostate cancer: The condition whereby cell mutation starts in the prostate gland. The 
cancer develops when prostate gland tissues start multiplying without regulation (ACS, 
2016). 
 
Prostate specific antigen (PSA) test: This test detects the blood level of PSA, a protein 
produced and released by the prostate gland in to the blood circulation (ACS, 2016). 
 
Digital Rectal Examination (DRE): is an examination of the lower rectum by a physician or 
nurse to examine the prostate for any abnormalities in size, lesions, symmetry, shape and 
texture (Itano et al., 2016). 
 
Attitude: is the way of responding towards a certain idea or situation (Dictionary, 2017). 
 
Practices: usual or customary actions (Collins, 2006). 
1.9 CHAPTERS OF THE STUDY 
The chapters of this study are as follows: 
Chapter1: Overview of the study 
Chapter2: Literature review 
Chapter3: Research methods 
Chapter 4: Discussion of results and data analysis 
Chapter5: Justification, limitations, recommendations and conclusions 
1.10 SUMMARY 
The introduction of prostate cancer and the overview of the study were presented here. In 
addition, the research question, aim, significance, setting, methods and statement of a 
problem were explained. Chapter 2 will present the literature review for this study.   
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CHAPTER TWO 
LITERATURE REVIEW 
2.1 INTRODUCTION 
Chapter 1 focused on the overview of the study, Chapter 2 will focus on the review of the 
literature related to prostate cancer worldwide, in sub-Saharan Africa and in South Africa. 
Primary prevention, secondary prevention, diagnosis and staging, signs and symptoms, 
knowledge, attitudes and practices of men and treatment of the disease will be discussed.  
2.2 PROSTATE CANCER INCIDENCE WORLDWIDE 
This disease is very common and has a high mortality rate globally (Adeloye et al., 2016). 
Other studies, such as by Agalliu et al. (2015), state that prostate cancer is one of the top 
cancers that cause death in males and found more often in males globally. According to the 
2012 Globocan statistics (WHO, 2012), approximately 1.1 million males had prostate cancer 
in the world, which was found to be at 15% compared to other cancers seen in males. In 
addition, 307,000 deaths were recorded in 2012, putting prostate cancer at the top of all 
cancers that cause death in men (6%) (WHO, 2012). 
 
The estimated incidences and mortality rate of prostate cancer according to the 2012 
Globocan statistics (WHO, 2012), are as follows: 
 
Table2.1 Prostate Cancer Estimated Incidence and Mortality Worldwide in 2012. 
Regions  Estimated incidence Estimated mortality 
Europe 420,000 101,000 
America 413,000 85,000 
Western pacific 153,000 46,000 
China 47,000 23,000 
South east Asia 39,000 25,000 
East Mediterranean  19,000 12,000 
 
Prostate cancer is seen more often in men in the United Kingdom, with 41736 incidences in 
2011, and is one of the top cancers that causes death in the United Kingdom with 10837 
mortalities in 2012 (Nderitu et al., 2016). Furthermore, in 2008, South America had 334,000 
incidences of prostate cancer with a 76,000mortality rate and the United States recorded 
238,590 incidences and a mortality rate of 29,720 (Torre et al., 2015, Siegel et al., 2013, 
Lozano et al., 2013). Nearly three-quarters (644,000) of the total registered incidences of 
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prostate cancer occur in developed countries. It was noted that this disease varies by 
continent, because of the differences in the utilisation of screening services and subsequent 
investigations that are widely used in North America and Europe (Torre et al., 2015). The 
Middle east, Southern African and Caribbean regions  have the highest mortality rate of 
prostate cancer (Torre et al., 2015, Agalliu et al., 2015) and a very low incidence in Asia and 
Europe. According to Agalliu et al. (2015), prostate cancer is found at great intensity in the 
Black community, but no reason is available to explain why, although it might be attributed to 
genetic makeup. 
 
According to studies carried out in Namibia, Sub-Saharan Africa (SSA) has a low prevalence 
of prostate cancer. According to the GLOBOCAN statistics (2012), prostate cancer has 23.2 
per 100,000 incidence and a mortality of 17.0 per 100,000 in SSA (WHO, 2012). 
Furthermore, in Sub-Saharan Africa, Nigeria is ranked first, followed by Democratic Republic 
of Congo and Uganda respectively, when considering the incidence of this disease 
(Atulomah et al., 2010).The high incidences and mortality rate of prostate cancer in Sub-
Saharan Africa have been associated with the low socio-economic status and genetic 
makeup as compared to other regions (Adeloye et al., 2016). Even though the prostate 
cancer incidence and mortality rate in Sub-Saharan Africa is high compared to the United 
States of America, there is a lack of data available in SSA (Kabore et al., 2014). 
According to GLOBOCAN statistics (2012), the  number of new cases for this disease in 
Southern African men is relatively large at 61.8 per 100,000 (WHO, 2012). In addition, 
Mofolo et al. (2015) found that the incidence and mortality rate of the disease in the 
Southern African Development Community region is 40.5 per 100 000 and 22.5 per 100 000 
of the population per year, respectively. The South African National Cancer Registry (2010), 
recorded 4652 incidences of prostate cancer, which were histologically diagnosed in South 
Africa during 2010 (CANSA, 2016). Moreover, White males are highly affected with 2864 
incidences, followed by Black males at 2448 incidences, Coloured males (702 ) and Asian 
males (125) (CANSA, 2016). A study conducted in the Western Cape by Heyns et al. (2011), 
at the Urology Clinic, Tygerberg Hospital, concluded that Black men presented with higher 
grade disease and higher serum Prostate Specific Antigen, received less potentially curative 
treatment and had a shorter follow-up than Whites and Coloureds. Furthermore,  the 
incidence rates of prostate cancer in South Africa is an underestimation of the burden of this 
disease, because not all geographic areas and socio-demographic groups have equal 
access to healthcare services and the National Cancer Registry (NCR) records include only 
microscopically verified cases (Babb et al., 2014). According to Babb et al. (2014), the 
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number of the new cases for this disease will increase in South Africa due to lifestyle 
changes and the fact that the South African population advances in age with life expectancy 
rising.  
2.3 PREVENTION AND EARLY DETECTION OF PROSTATE CANCER 
The incidence of this disease continues to rise in many countries. According to the American 
Cancer Society (ACS, 2016), some risk factors for prostate cancer cannot be prevented, 
such as age, being male, and having a family history of this disease. However, the risk of 
developing this disease can be minimised by lifestyle modification, such as smoking 
cessation, exercise and weight control measures (Cuzick et al., 2014). The high mortality 
rate of prostate cancer worldwide (307 per 100,000) could be reduced by effective 
implementation of primary prevention measures. Prostate cancer screening is an attempt to 
detect disease in asymptomatic men, even though screening and management of early 
prostate cancer is one of the most challenging issues in healthcare (Cuzick et al., 2014). 
Many healthcare professionals are unable to notice the early signs and symptoms of 
prostate cancer. Several studies conducted across the world have different findings 
concerning the use of PSA and the disagreement about the utilisation of this method still 
exists (Nakandi et al., 2013). 
2.3.1 Primary prevention of prostate cancer 
Primary prevention of prostate cancer is an effort  by healthcare professionals to increase 
public knowledge and to decrease prostate cancer incidence by encouraging lifestyle 
modification (Cuzick et al., 2014). Given the high incidence of prostate cancer globally, it is 
very important to prevent the disease; eating unhealthy food, high body weight, high alcohol 
drinking and more body fat, all contribute towards the high number of new cases of the 
disease (ACS, 2016). 
Primary prevention interventions for prostate cancer that are recommended by several 
studies around the world include the prevention of environmental factors, such as ionising 
radiation, ultraviolet radiation from the sun and cadmium, which have been linked to prostate 
cancer (Cuzick et al., 2014). The connection between increased levels of PSA and cadmium 
was found in a study carried out in 295 men(Cuzick et al., 2014), therefore, men need 
education on reduction of exposure to ionising radiation and cadmium metal.  
Several studies and organisations have indicated that, in order to reduce the incidence of 
prostate cancer, it is important to monitor diet, manage weight and to engage in exercises. 
According to Cuzick et al. (2014), high body-mass index (BMI) plays a role in increasing the 
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incidence of Stage 4 prostate cancer. Analysis of the Prostate Cancer Prevention Trial 
(PCPT) showed similar findings that prostate cancer is linked to increased BMI (Cuzick et 
al., 2014). The best nutritional and exercise assurance that can be given to minimise the risk 
of the disease is to eat different kind of fruits and vegetables daily, exercise and to maintain 
a normal body-mass index(Kushi et al., 2012). The link between exercise and this disease 
was investigated in a study conducted in western countries by putting together the results of 
two studies (Kushi et al., 2012). Overall, the risk of prostate cancer can be reduced by 
engaging in regular exercise. According to Kushi et al. (2012), some studies have shown 
that tomato products and soybeans are associated with decreased risk, even though the 
evidence is not convincing. Furthermore, men are advised to eat white meat rather than red 
meat as an attempt to reduce prostate cancer incidence. In addition, the American Cancer 
Society (2012) has recommended regular exercises, cutting down on alcohol consumption, 
maintaining a normal weight, not eating food high in calories and that organisations should 
work together to avail an affordable and balanced diet to people in rural areas (Kushi et al., 
2012). 
Smoking can also lead to the development of this disease. According to Cuzick et al. (2014), 
men who smoke have a higher chance of dying from this disease than men who don’t 
smoke. Therefore, encouragement of cessation of tobacco smoking is paramount when 
addressing prostate cancer prevention. 
Finally, educating men about treating urinary tract infection is important. Studies have shown 
that males who have experienced urinary tract infections have a higher possibility of having 
prostate cancer (Cuzick et al., 2014). The study conducted by Cuzick et al. (2014)concurred 
that urinary tract infection increases the chances of developing this disease. 
2.3.2 Early detection 
Early detection is defined as any intervention implemented to identify potential for existence 
of a disease in asymptomatic individuals (Itano et al., 2016). The main aim of secondary 
prevention or screening is to reduce the possibility of developing the disease at the 
asymptomatic stage as a screening service. The screening tests used to investigate this 
disease are the prostate specific antigen (PSA) and digital rectal examination (DRE) 
(Nakandi et al., 2013). According to the American Urological Association (2012), PSA is the 
only method recognised to control prostate cancer through early detection (Brett, 2013). 
Furthermore, several studies have shown that PSA can discover the disease at an infant 
stages (Brett, 2013). 
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Men who have siblings who are diagnosed with prostate cancer should commence testing 
when they reach 40 years, because they have a high chance of developing this disease 
since it runs in the family (ACS, 2016). The screening for prostate cancer, based on PSA 
biomarkers, is the most cost-effective method for the detection of early disease (Kushi et al., 
2012). In addition, the PSA screening for prostate cancer is seen as very important as it can 
reveal results that may lead to recommendations for biopsy and other tests that can also 
help to diagnose disease. 
The American Urology Association (2013) states that PSA screening should not be done for 
men below 40 years or over 70 years, or those with less than 10 to 15 years life expectancy. 
However, for men between 55 and 64 years, the decision to perform screening should be 
individualised and the benefits and harm be weighed (Brett, 2013). Men who are between 
ages of 40 and 75 are encouraged to perform PSA screening tests even though some 
organisations leave the decision to the patients and the health professional. 
Despite the controversies surrounding PSA screening, large population-based studies have 
shown increased survival benefits in the early detection of prostate cancer when compared 
with no active therapy in men with moderately and poorly differentiated disease (Nakandi et 
al., 2013). In addition, the study conducted in South African Black men suggested that a lack 
of PSA testing, more especially in rural areas, is contributing to late presentation of prostate 
cancer (CANSA, 2016). According to the same study, men in rural areas present to the 
healthcare setting when the disease has spread (CANSA, 2016).   
According to the Cancer Association of South Africa (CANSA), secondary prevention plays a 
vital role in reducing the number of deaths caused by prostate cancer. PSA testing can 
reduce the chances of developing the disease by 31% when compared to men who are not 
screened (CANSA, 2016). Some studies have also shown that the recent decline in cancer 
mortality observed in several countries was due to early detection (Nakandi et al., 2013). 
Moreover, the American Cancer Society (2013) states that a prospective randomised trial 
from Canada suggests that prostate cancer mortality can be minimised widely through PSA 
screening (Brett, 2013).   
Variation in guidelines concerning prostate cancer prevention and limited knowledge 
amongst men, contribute to the challenges that are faced by health professionals when 
dealing with the disease prevention. This lack of knowledge has been confirmed by several 
studies conducted in Africa (Mofolo et al., 2015, Nakandi et al., 2013, Kabore et al., 2014), 
which state that men are not aware of prostate cancer symptoms and it is difficult for them to 
respond when experiencing these symptoms. A recent study conducted in Uganda on 295 
respondents, indicated that 47.9% of men were not aware of the screening services for this 
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disease (Nakandi et al., 2013). An additional study was conducted in Burkina Faso by 
Kabore et al. (2014), which showed only 8.2% of men were aware of the PSA test. 
The uptake of prostate cancer screening was investigated in many studies globally. The low 
uptake of screening services was due to fear of the disease, lack of knowledge, 
embarrassment and perceived low risk, as shown by So et al. (2014), who indicated that in 
the Chinese and Taiwanese populations the uptake of prostate cancer screening was 12.4% 
and 29.4% respectively. The study further indicated that amongst African Americans and 
Canadians, the uptake is 36% and 47.5% respectively (So et al., 2014). 
Another method commonly used by physicians for screening for this disease is DRE. 
According to the Cancer Association of South Africa (CANSA, 2016), DRE is an examination 
of the prostate gland by a physician to check for any changes that might have occurred on 
the prostate. Benign Prostate Hyperplasia is differentiated from prostate cancer through 
inserting a finger into the anus of the patient by a health professional. The DRE has some 
advantages, because it can detect large masses when they are present, is less expensive 
when incorporated into routine screening and the method is quick to perform (Winterich et 
al., 2009). However, the method has the disadvantages of missing small prostate tumours, 
having relatively poor specificity for prostate cancer and the effectiveness depends largely 
on the skill and competence of the healthcare professional (Winterich et al., 2009). 
The mortality benefit of DRE when used alone is not yet established, because no trials have 
been done (Bell et al., 2014). However, DRE is performed on well-counselled men and those 
who have elevated PSA levels and wish to be screened (Horwich et al., 2010). Even though 
the method is widely used, men are not aware of this screening method, as several studies 
have indicated a small percentage of men mentioned the method. A study carried out by 
Kabore et al. (2014), indicated only 6.2% of respondents within the group stated to be aware 
of the DRE screening method. 
2.3.3 Cancer prevention and detection campaigns 
In South Africa, CANSA focuses its campaigns on the most common cancer affecting men 
such as prostate, colorectal, Kaposi sarcoma, lung and bladder cancer. However, there is no 
information that could be found on the prostate cancer campaigns internationally and in 
South Africa. Information available is about breast cancer and cervical cancer. 
2.4 SIGNS AND SYMPTOMS OF PROSTATE CANCER 
Prostate cancer usually grows slowly and some of the symptoms may not necessarily 
indicate it, therefore no clear defined signs and symptoms are known (PCFSA, 2013). 
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Ejaculation and prostatitis have signs similar to those of prostate cancer. Moreover, no 
symptoms are seen on men while the cancer is starting to grow. 
Prostate cancer usually shows symptoms when the growing tumour is blocking the urine 
pipe, hence interrupting the flow of urine. The well-known symptoms of this disease are: 
back pain, blood stained urine, experiencing problems with urination, inability to hold back 
urine, itching urine, having pain during ejaculation and urinating more often at night (PCFSA, 
2013). According to the Canadian Cancer Society (2014), the signs of early stage prostate 
cancer are problems with urination and difficulty in achieving or maintaining erection and 
painful ejaculation. The American Cancer Society (2016) indicates that more advanced 
prostate cancer causes symptoms such as painful hips, back pain, chest pain and mentions 
that men can also experience weakness of lower extremities, urine incontinence and bladder 
problems (ACS, 2016). 
2.5 DIAGNOSIS AND TREATMENT OF PROSTATE CANCER 
Many procedures can be performed to diagnose prostate cancer; however, microscopic 
examination and biopsy are used to confirm the presence of this disease, as well as trans-
rectal ultrasound and cystoscopy. Before taking a biopsy for examination, DRE can be 
performed to assess the state of the urine pipe and the prostate for size, texture and 
position. Cystoscopy is used for examining the bladder and trans-rectal ultrasonography is 
used for examining the picture of the prostate. However, studies are on-going, searching for 
new ways of improving the diagnostic accuracy of trans-rectal ultrasound-guided biopsy, 
which currently is the basic way to diagnose prostate cancer (Tefekli and Tunc, 2013) and 
recently, magnetic resonance imaging (MRI) is playing a pivotal role in diagnosing  prostate 
cancer (Tefekli and Tunc, 2013). The utilization of MRI in diagnosing prostate cancer was 
confirmed by many published studies. Finally, several interventions are available for treating 
prostate cancer. 
2.5.1 Diagnosis of prostate cancer 
According to the American Cancer Society (2016), biopsy is the removal of the small sample 
of the prostate gland for examination using a microscope (ACS, 2016). The main method 
utilised to diagnose this disease is a core needle biopsy, which is normally done when 
certain symptoms are present or when DRE suggests any changes in the prostate gland and 
when the PSA is elevated. A general surgeon and urologists perform this procedure. 
Prostate biopsy is done with the help of trans-rectal ultrasound (TRUS), which helps the 
healthcare professional to visualise the prostate gland (ACS, 2016). The procedure is 
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performed under general anaesthesia and it is the precise way of coming up with the 
diagnosis of prostate cancer. Most men can experience blood stained semen, which 
normally lasts some weeks after biopsy. The American Cancer Society (2016) states that 
prostate cancer can still be missed if biopsy needles fail to pass through it, hence giving a 
false, negative result, which may force healthcare professionals to repeat the biopsy (ACS, 
2016). Barrett and Haider (2017) state in their recent study that trans-rectal ultrasound is 
prone to sampling error because it randomly samples 1% of the gland. Several studies have 
established that TRUS biopsy under estimates prostate cancer aggressiveness in 
approximately one-third of cases.  
Computed tomography is an instrument used by many healthcare professionals for the 
diagnosis and management of cancer. The computed tomography scan (CT) uses X-rays 
and computers to make 3-dimensional images of inside the human body (ACS, 2016). CT 
scans, compared to traditional X-rays, can produce detailed images of the bones, organs 
and tissues therefore, they can indicate if the disease is growing into other organs, such as 
the pelvis. It is also done to estimate prostate size by showing detailed images of the 
prostate gland. MRI is an imaging method that uses both radio waves and a computer to 
make a detailed image of the body organs and structures to evaluate extra-capsular 
penetration beyond the gland itself (ACS, 2014). In addition, MRI scans can indicate if the 
cancer has spread to other nearby organs and has the ability to produce good images of the 
prostate. 
 According to Barrett and Haider (2017), MRI scans have now been extensively validated for 
the detection of prostate cancer, and they indicate that MRI should be used as a baseline 
diagnosing method to identify the misclassified patients. An MRI scan is important because it 
offers additional information on the accuracy of tumour localisation and staging and it 
identifies the anterior disease, which has systematically been missed by standard trans-
rectal ultrasound-guided biopsy (Tefekli and Tunc, 2013, Barrett and Haider, 2017, ACS, 
2016). Moreover, Tefekli and Tunc (2013) indicated dynamic contrast-enhanced MRI by up 
to 90% in detection and localisation of prostate cancer. 
 
According to Tefekli and Tunc (2013), a more recent study investigating the role of MRI-
targeted TRUS-guided trans-perineal fusion biopsy in the diagnosis of this disease, identified 
that 58% of samples, which had a history of negative TRUS-guided biopsies, had prostate 
cancer. The study, based on the above findings, concluded that MRI-targeted TRUS-guided 
trans-perineal fusion biopsy provides high detection rates of clinically significant tumours. 
Furthermore, the enhanced MRI is better than conventional CT and MRI in detecting lymph 
nodes that contain cancer (Tefekli and Tunc, 2013). 
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MRI accuracy however depends on certain variables, such as patient selection criteria, 
grade and stage of disease, MRI sequences used, and healthcare professional expertise, 
which support the recent attempts to standardise MRI acquisition and interpretation (Barrett 
and Haider, 2017). Tefekli and Tunc (2013) also indicated that this technique still has some 
limitations, and therefore systematic biopsies should be used to diagnose prostate cancer. 
This conclusion was made based on a recent meta-analysis report, which showed a median 
prostate cancer detection rate of 42% (Tefekli and Tunc, 2013). 
The most commonly used diagnostic tests for prostate cancer in South Africa are trans-rectal 
ultrasound, cystoscopy and trans-rectal biopsy (PCFSA, 2013). The cystoscopy is a 
procedure whereby the interior of the urethra and bladder are examined (PCFSA, 
2013).These tests are available in hospitals in South Africa 
2.5.2 Treatment of prostate cancer 
To start treatment of this disease different factors are taken into consideration, such as 
performance status, grade and stage of the cancer, age and the preference of the patient 
(PCFSA, 2013, ACS, 2016).  Each treatment option has side effects that can have an impact 
on the patient’s quality of life and sometimes treatment options are used in combination. 
Horwich et al. (2010) indicated that before men start treatment for prostate cancer, the side 
effects of treatment should be explained to them, they should know they might experience 
sexual dysfunction, infertility and incontinence. Furthermore, Barrett and Haider (2017) also 
indicated in their study that approximately 60% of patients will develop erectile dysfunction 
after radical therapy and 30% of men will experience severe urinary incontinence. During 
treatment of prostate cancer, men are observed and closely monitored with PSA blood tests, 
DRE, and trans-rectal ultrasound at regular intervals to determine the progress of the 
disease. If any changes are shown in the test results, further treatment modalities will be 
planned and discussed (ACS, 2016, Horwich et al., 2010).  
Watchful waiting is one of the methods used in the management of this disease.  According 
to the American Cancer Society (2016) and Prostate Cancer Foundation of South Africa 
(2013), ‘watchful waiting,’ is a period when men with prostate cancer are monitored closely 
by healthcare professionals through regular DRE and repeated biopsies. Other countries 
perform MRI to identify early signs of disease progression and PSA blood tests without 
treating the disease (ACS, 2016, PCFSA, 2013).The ‘watchful waiting’ approach is 
recommended for men who have Stage I prostate cancer and are elderly with other co-
morbidities that may limit their lifespan. In addition, males found to have this disease at a 
younger age and are not experiencing any prostate cancer symptoms may be considered for 
active surveillance (ACS, 2016). Some men opt for this approach because of the fear of side 
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effects from surgery, chemotherapy and radiation. Many studies have not approved 
hormonal therapy, an approach that can be used with ‘watchful waiting’ in men who are not 
ready for active treatment even though there are experiencing some symptoms of the 
disease  (Horwich et al., 2010). Although there is growing agreement for men with no 
symptoms of prostate cancer to be offered ‘watchful waiting’ as a management approach, 
some men and their families find it inappropriate to choose this approach. These men state 
they are ready to face the side-effects of radiotherapy, chemotherapy and/or surgery with the 
aim of removing or destroying the prostate cancer (Brett, 2013). Finally, different countries 
implement different criteria to include men into active surveillance protocol and most 
countries include patients with a PSA <10ng/mL (4ng/mL and lower) and those who have 
less than three positive TRUS biopsies (Tefekli and Tunc, 2013).  
Surgery is the most common method used in the management of prostate cancer, by 
removing all or part of the prostate. The main type of operation conducted for prostate 
cancer at an infant stage is radical prostatectomy (ACS, 2016, PCFSA, 2013), which is seen 
as the gold standard while managing localised cancer. In addition, this surgery can be 
utilised in many ways for treatment of prostate cancer. The radical prostatectomy used in the 
past by surgeons was open approach surgery, whereby the surgeon cut the skin to remove 
the prostate and nearby tissues, and during the operation, the seminal vesicles were 
removed. This treatment approach is used when the cancer is confined to prostate. 
According to the American Cancer Society (2016), this procedure can be performed in two 
ways, such as radical retro-public prostatectomy and radical perineal prostatectomy (ACS, 
2016). The radical retro-public prostatectomy is when the surgeon or oncologist makes an 
incision in the lower abdomen while the patient is under general anaesthetic, and a lymph 
node biopsy can be taken during the operation based on the results of the PSA level and 
prostate biopsy. In radical perineal prostatectomy, the surgeon makes an incision in the 
perineal region, however, in this approach lymph nodes cannot be removed and it is not 
used often because it leads to erection problems (ACS, 2016). 
Presently, modern technology and techniques are used to carry out prostatectomy. Two 
minimally invasive laparoscopic approaches are used to remove the prostate. According to 
the American Cancer Society (2016), robotic-assisted laparoscopic radical prostatectomy is 
performed  with the help of the Da Vinci system (ACS, 2016), which is controlled from the 
operating room by an experienced surgeon to remove the prostate. Furthermore, radical 
prostatectomy is a dominant technique among surgeons in the United States because of 
widespread advertisements and because it makes the operation more easy for the surgeons 
to perform using the arms of the machine (Tefekli and Tunc, 2013). According to Tefekli and 
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Tunc (2013), cancer that is still confined to the prostate can be managed best by the use 
ofrobotic-assisted radical prostatectomy.  
Another approach is laparoscopic radical prostatectomy, whereby the doctor’s uses 
equipment inserted through the openings done in the abdomen. The surgeon is able to see 
inside the body through a video camera, which is part of the instrument (ACS, 2016). These 
modern technological advances have raised the expectations of patients with localised 
prostate cancer. However, a randomised controlled trial comparing radical prostatectomy 
and active waiting conducted by the Scandinavian Prostate Cancer Group (SPCG) has 
shown that 80% of patients who underwent radical prostatectomy developed erectile 
dysfunction (Horwich et al., 2010).  
Radiotherapy, another radical treatment for prostate cancer, is a local treatment that uses 
high-energy waves similar to x-rays to eliminate cancer cells or make the tumor smaller. 
Advances in technology has made it easy for radiation oncologists to come up with other 
treament ways, such as conformal radiation therapy (CRT), proton beam radiation and 
intensity modulated radiation therapy,which do not interfere with nearby organs(Tefekli and 
Tunc, 2013). These methods help to reduce side-effects of radiation while increasing the 
effectiveness of the therapy.  Moreover, radiotherapy is used for localised prostate cancer 
and when the cancer is still at a low stage (ACS, 2016). Radiotherapy  can be used as 
adjuvant therapy after surgery and/or to keep prostate cancer under control if it is more 
advanced. 
 
Radiotherapy can be given in two different ways, such as external beam radiation or internal 
radiation ( brachytherapy). With external beam radiation therapy (EBRT), the precise dose is 
given to a patient from outside his body. EBRT can be used to relieve some symptoms when 
the cancer is found in other organs and can be utilised to cure cancer when it is detected at 
an early stage (ACS, 2016). Before a patient starts treatment, he undergoes a simulation 
session, which helps with creating an image of the defined treatment volume;in addition, the 
CT and MRI scans and making of a body cast prior treatment is very important (ACS, 2016, 
PCFSA, 2013). Treatment is given in fractions and it lasts only a few minutes in an out-
patient clinic over a period of 7 to 9 weeks, and the patient does not experience any pain or 
discomfort during the delivery of treatment.  
According to the Prostate Cancer Foundation of South Africa (2013), external beam radiation  
can be delivered through different methods, such as three-dimensional conformal radiation 
therapy (3D-CRT) and intensity modulated radiation therapy (IMRT) (PCFSA, 2013). The 
3D-CRT is used to aim radiation beams at the prostate from different angles and normal 
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tissues are avoided to limit doses to them, while IMRT is complex method of 3-dimensional 
therapy. On top of creating good beams from different angles, the machine is computer-
driven and it moves around the patient as the radiation doses are delivered (ACS, 2016).  
Finally, the new machine that is in use is image-guided radiation therapy, which has imaging 
scanners built into it. The radiation therapist is able to create pictures of the treament field 
and make some changes before delivering the dose. However, external beam radiation has 
some side-effects such as diarrhea, rectal leakage, frequency of urination, burning sensation 
while passing urine, blood in the urine and fatigue, while late side effectsare urinary 
incontinence and proctitis (ACS, 2016).  
Brachytherapy, which is called seed implantation by other sources, is a method in which 
radiotherapy materials are placed directly into the prostate with the guide of imaging tests, 
such as trans-rectal ultrasound, CTscans or MRI (PCFSA, 2013).  According to the 
American Cancer Society (2016), brachytherapy is utilised in males with low-grade prostate 
cancer and can be used together with teletherapyin those with greater chances of 
deveolping stage 3 or 4 of prostate cancer (ACS, 2016). However, brachytherapy use in 
prostate cancer is limited due to factors such as urinary problems and large prostate glands. 
When the prostate gland is enlarged, it is not easy to insert the radioactive materials in the 
required place of treatment. Brachytherapy is done in two approaches, being permanent and 
temporary. With the permanent approach, radioactive material, such as iodine-125, is placed 
through the perineal region into the prostate gland with the help of thin needles (ACS, 2016). 
The needles will be removed, while the seeds are left in the prostate for months to discharge 
low doses of radiation.This technique is not commonly used in hospitals,however, the  
technique causes less problems for the patients because it does not affect other organs 
which are not part of treatment field (ACS, 2016). Patients may only experience some pain in 
the insertion area and urine may be reddish-brown. 
Cryotherapy (cryo-ablation) is utilised to manage low-grade prostate cancer through the 
utilisation of extremely low temperatures to destroy cells that cause cancer (PCFSA, 2013). 
The technique is used when the cancer recurs after primary treatment with radiation therapy. 
This procedure is done by a doctor using the trans-rectal ultrasound to guide needles 
through the perineum into the prostate (ACS, 2016). During the procedure, the urethra is 
kept from freezing by circulating warm salt water through a catheter inserted into the bladder 
through the penis. Cryotherapy can cause some problems for the patient, such as erectile 
dysfunction, urinary problems and blood in the urine, for some days after the procedure 
(ACS, 2016). 
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The other treatment option for prostate cancer is hormonal therapy. Also known as androgen 
suppression therapy, hormonal therapy prevents the production of testosterone from the 
testicles and adrenal gland, thus shrinking the prostate cancer and slowing down its growth 
(Horwich et al., 2010). This treatment option does not provide a cure for prostate cancer; 
however, it can be given prior to other treatment modalities with the aim of reducing the size 
of the tumour. In addition, hormonal therapy can be used in metastatic disease where 
surgery is seen as impossible to perform and/or when the prostate cancer comes back after 
primary treatment (ACS, 2016). 
According  to Horwich et al. (2010), luteinizing hormone-releasing hormone agonist (LHRHa) 
should be recommended to men receiving radiation therapy for high-risk disease. Examples 
of LHRHa commonly used in the United States of America include, Leuprolide (Lupron, 
Eligard), Goserelin (Zoladex), Triptorelin (Trelstar) and Histrelin (Vantas). LHRH agonists 
can be given as an injection and again the surgeon can insert small implants underneath the 
patient’s skin from once a month up to once a year (ACS, 2016). Luteinizing hormone - 
releasing hormone antagonists, such as the Degarelix (Firmagon), work like the LHRH 
agonists, the only difference is it has no potential to make the tumour grow fast as compared 
to the LHRH agonists (PCFSA, 2013).  Furthermore, CYP17 inhibitors such as Abiraterone 
(Zytiga) can be used as a hormone therapy because it blocksCYP17, therefore stopping the 
cancer cell from producing androgens (ACS, 2016). 
Chemotherapy is an agent used to destroy cancer cells and slow the growth of prostate 
cancer. More research  
studies are being done to establish the effectiveness of chemotherapy after surgery when 
the disease is still at an early stage, however, these agents are not standard treatment of 
early state prostate cancer (ACS, 2016). Chemotherapy is a systemic treatment, which is 
utilised when the disease is not responding to hormonal therapy, and can be used at an 
early stage to slow down the progression of the disease (Tefekli and Tunc, 2013).  
According to the American Cancer Society (2016), there are various kinds of agents utilised 
to treat prostate, such as Docetaxel (Taxotere), Cabazitaxel (Jevtana), Mitoxantrone 
(Novantrone) and Estramustine (Emcyt). Docetaxel is the first drug given in the chemical 
management of this disease, used together with other agents like Prednisone. This agent is 
used for patients who shows signs and symptoms of castration-refractory disease (Horwich 
et al., 2010). According to a large international multicentre stage III trial (TAX327), Docetaxel 
is the best compared to other treatments in prolongation of survival rate, as shown by a 50% 
decrease in PSA for half of the patients who took part in the study (Horwich et al., 2010). 
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However, Mitoxantrone can be used if it is impossible to use Docetaxel, because of contra-
indications (ACS, 2016). This drug is important in the sense that it reduces symptoms, 
leading to a better quality of life and it also helps men to live longer (PCFSA, 2013).There 
are however many problems, such as myelosuppression, mucositis, nausea and vomiting 
and alopecia, associated with chemotherapy. 
The last method for treating prostate cancer is vaccination. Sipuleucel-T, also known as 
Provenge, is the only vaccine utilised to manage prostate cancer when it is advanced 
(Horwich et al., 2010). While the vaccine is used to improve the immune system of the body, 
it is also aimed at treating advanced disease that is not responding to hormonal therapy. 
This vaccine is not readily available in the market and is manufactured from the patient’s 
own blood (Horwich et al., 2010). 
2.6 STAGING AND GRADING OF PROSTATE CANCER 
Staging in oncology is a procedure used by health professions when describing the 
magnitude of the disease and the state of metastasis. The healthcare professionals estimate 
the likelihood of spread of prostate cancer before treatment is given to the patient (Cosma et 
al., 2016). Normally cancer-staging evaluation happens before and after the tumour is 
removed, which is called clinical and pathological staging respectively. Clinical staging relies 
on DRE results, while pathological staging depends on the estimate made through 
examination of the removed tissue (Cosma et al., 2016). Pathological staging is more 
accurate compared to clinical staging, because it can provide direct insight into the extent of 
the disease.  
The commonly used staging system for prostate cancer is the TNM system, which is 
recognised by the Union for International Cancer Control (UICC) and also the American Joint  
Committee on Cancer (AJCC) (Cosma et al., 2016). This cancer staging system is based on 
determining the size of the tumour (T stage), the involvement of nearby lymph nodes (N 
stage) and the spread, or not, to other organs (M stage) (Cosma et al., 2016, ACS, 2016). In 
addition, the PSA level at the time of diagnosis and the Gleason score based on the prostate 
biopsy can be used to determine the stage of the tumour. See Table 2.2 for the TNM staging 
below. 
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Table 2.2: AJCC (2010) staging of prostate cancer 
Primary tumour (T) 
TX Tumour cannot be assessed 
T0 No evidence of primary tumour 
T1 Cancer present but not palpable on DRE nor visible by imaging 
T1a Tumour incidentally found in 5% or less of tissue resected 
T1b Tumour incidentally found in more than 5% of tissue resected 
T1c PSA elevated, not palpable however tumour identified by needle biopsy 
T2 Tumour confined within prostate 
T2a Tumour confined to half of one lobe or less 
T2b Tumour confined to more than half of one lobe, but not both lobes 
T2c Tumour is in both lobes but within the prostatic capsule 
T3 Locally extensive cancer 
T3a Penetration of prostate capsule on one or both sides 
T3b Tumour invades seminal vesicles 
T 4 Tumour invades adjacent organs, such as the urethral sphincter, the bladder 
and the rectum  
Regional lymph nodes (N) 
NX Nearby lymph nodes not sampled 
N0 No regional lymph node metastasis 
N1 Regional nodes involvement 
Distant metastasis (M) 
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MX Distant metastasis cannot be evaluated 
MO The disease has not metastasised 
M1 Distant metastasis 
M1a The cancer has spread to regional lymph nodes (outside the pelvis) 
M1b The cancer has spread to the bones  
M1c The cancer has spread to other parts of the body, such as lung, liver and brain, 
with or without bone disease 
Source: (Itano et al., 2016) 
Prostate cancer is categorised in four stages being Stage I, II, III and IV. Stages I and II are 
called early, while Stage III is when the cancer has spread to nearby tissues and Stage IV is 
when cancer has metastasized (Cosma et al., 2016, PCFSA, 2013). Prostate cancer Stages 
I and II are confined to the prostate, while Stages III and IV are extra-prostatic stage. In 
addition, the Prostate Specific Antigen and Gleason score are also used in the disease 
staging by the American Joint Committee on Cancer (AJCC) (PCFSA, 2013). 
Table 2.3: Stage grouping  
Stage I T1a N0 M0 
Stage II T1a 
T1b 
T1c 
T1  
 T 2 
N0 
N0 
N0 
N0 
N0 
M0 
M0 
M0 
M0 
M0 
Stage III T3 N0 M0 
Stage IV T4 
Any T 
N0 
N1 
M0 
M0 
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Any T Any N0 M1 
Source: (Itano et al., 2016) 
Finally, the prostate cancer cells can be graded by looking at them through a microscope. 
According to the PCFSA (2013), grading of prostate cancer determines how abnormal the 
cancer cells appear when examined under the microscope. A pathologist examines the 
genotype or phenotypes of both normal and abnormal cells. The abnormal cells do not 
resemble the mother cells and look abnormal. Based on the results, abnormal cells are 
graded. According to the PCFSA (2013), prostate cancer is classified as grade one or grade 
four. Grade one, is when the abnormal cells looks like normal ones and the cells are not 
multiplying very fast, while grade 4 cancer cells look different and if not treated, they spread 
quickly (PCFSA, 2013). 
2.7 KNOWLEGDE, ATTITUDE AND PRACTICES OF PROSTATE CANCER AMONG MEN 
 
Men have shown limited knowledge concerning prostate cancer (Nakandi et al., 2013). A 
study conducted in Uganda has shown that 37.4% of  men were not aware of people 
affected by this disease, but 21.1% were able to identifiy the age that is commonly affected. 
Half of the men who were part of the study could not identify predisposing factors of this 
disease but 10.3% knew symptoms,while 50.1% were not aware of prostate cancer 
symptoms (Nakandi et al., 2013). In addition, the study conducted in South Africa by Mofolo 
et al. (2015) also identified a poor knowlegde in Black African men.The educational status is 
playing a role in their knowledge regarding this disease (Kabore et al., 2014). Furthermore, a 
study conducted in Nigeria by Ogundele and Ikuerowo (2015) shares the same sentiment 
when stating there is poor knowledge of the disease within male population and voluntary 
screening for the disease is very low. In addition, disbelief and misconception among African 
men concerning prostate cancer has also been reported as a contributing factor to late 
reporting to healthcare settings (Ogundele and Ikuerowo, 2015, Kabore et al., 2014). 
Despite the poor knowledge regarding prostate cancer, men also have a negative attitude 
toward prostate cancer screening. Studies in Uganda have indicated that 77% of men had 
never considered undertaking screening due to a negative attitude towards prostate cancer 
(Nakandi et al., 2013). Another prominent reason for men not to take part in any cancer 
preventative measures is the feeling that they cannot get prostate cancer, which is 
accompanied by a lack of knowledge and avoidance of fear and anxiety (Azubuike and 
Okwuokei, 2013, Kabore et al., 2014). 
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Many people, men included, tend to involve religious practices in dealing with cancer and 
health-related issues because the church provides a social network of support, coping and 
an interpretive framework for distress or suffering (Allen et al., 2014). A survey done on 
churches of various sizes and socio-economic strata, dimensions of religiousness and 
cancer screening behaviour among church-going Latinos in the United States of America, 
found that 89% of men know of screening services for prostate cancer (Allen et al., 2014). 
Religions usually influence beliefs and cultural values and this in turn influences health 
behaviour of men towards screening (Allen et al., 2014). Furthermore, religious and cultural 
beliefs, lack of knowledge, access to hospitals, financial constraints and fear are the most 
common reasons for non-participation in prostate cancer screeening among men in Africa 
(Rebbeck et al., 2011). In Africa no information is available about the association between 
religious and cultural beliefs concerning non-participation in prostate cancer screening. 
2.8 SUMMARY 
This chapter discussed the literature focusing on the incidence worldwide, in particular Africa 
and South Africa. Prevention, screening, risk factors and signs and symptoms of prostate 
cancer were also presented. 
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CHAPTER THREE 
RESEARCH DESIGN AND METHODS 
 
3.1 INTRODUCTION 
Chapter 2 focused on the literature review, Chapter 3 will explain the design and methods, 
setting, sampling and population, process of data gathering, data management and storage, 
instrument development, validity and reliability and finally the ethical considerations for the 
study. 
3.2 RESEARCH SETTING 
A research setting is a physical location in which data collection takes place (Grove et al., 
2013). The setting for this study was Muldersdrift, in an area called Ward 23, also known as 
Video, which forms part of the West Rand District Municipality. The West Rand District 
Municipality is situated on the south-western edge of the City of Tshwane and City of 
Johannesburg metropolitan areas respectively (MCLM, 2017). Muldersdrift is a semi-urban 
area with few developments. According to Rwamugira et al. (2017), Muldersdrift has a 
population of approximately 19,959, with a high number of the population ranging from 20 to 
34 years of age. According to the South African community profile database (Frith, 2011), 
Ward 23 has 436 males. The majority of the men are in the age group of 20 to 35; this is an 
estimated figure, as it is not easy to know how many people actually live in Ward 23, 
because more than one family can occupy one house. 
Muldersdrift is comprised of people from different cultural backgrounds and who speak 
different languages, such as isiZulu, Setswana, isiXhosa, Northern Sotho and Tsonga. The 
most common languages are Setswana, English and isiZulu. In addition, the majority of 
people in this area have obtained some secondary school education (MCLM, 2017). Ward 
23 consists of an informal settlement with an unknown number of informal dwellings, as 
homes are continuously being erected, as well as 214 small brick houses built as part of the 
Reconstruction and Development Programme of the National Government.  The informal 
houses have no running tap water and residents use communal taps, which provide water fit 
for drinking. Residents in the informal houses use pit latrines, even though it is not clear how 
many yards have them. The informal homes do not have electricity, but some have illegal 
electricity connections, which are taken from the small brick houses constructed by the 
Government; the illegal electricity lines are seen in the small passages of the informal 
settlement. The internal roads are tarred and well labelled. 
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The residents of Ward 23 use the Muldersdrift Primary Health Clinic for accessing 
healthcare. The clinic is nurse-led and provides a wide range of services, such as 
awareness of non-communicable diseases, training and prevention services, psychosocial 
support and treatment-related services. An enrolled nurse visits Ward 23 on a daily basis to 
provide health education to its residents. 
3.3 RESEARCH DESIGN 
The research design is a plan utilised to address the research question and the aim of the 
study (Grove et al., 2013). This method constitutes the collection, measurement and analysis 
of data.  
A door-to-door survey, designed for the purposes of this study, was utilized (described 
below). According to Grove et al. (2013), a survey  is a method of collecting data as reported 
by respondents through a survey questionnaire administered to them, who then answer the 
questions asked. This non-experimental design is used to collect data about people via 
direct questioning or use of questionnaires (Grove et al., 2013). According to Creswell 
(2013), a survey is used to collect data about attitudes and common practices of a 
population. In addition, it may be used to generalise results to a larger population and study 
relationships between variables (Creswell, 2013). 
During a door-to-door survey, the researcher visits respondents in their household. The 
method was applicable to this study because it allowed the researcher to interact with the 
respondents, which had the potential to improve the accuracy of the data (Grove et al., 
2013).This verbally administered survey was better because the population have low literacy 
level. This design was selected due to the fact it can gather data from a big sample size in a 
less expensive manner. In addition, the design has the ability to compare the association 
between two variables, but the causes of these two variables are not determined (Creswell, 
2013). 
3.4 RESEARCH METHODS 
This section includes description of the study population, sampling, data analysis and 
information gathering process. 
3.4.1 Population 
The population is the total number of people that the researcher has an interest in studying 
(Grove et al., 2013). The population was all men in Ward 23, Muldersdrift, whilst the target 
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population was all men who met the sampling criteria (Grove et al., 2013).The target 
population for this study comprised all men, who were 40 years and above residing in the 
semi-rural area called Muldersdrift.  Men 40 years and older were selected for this study 
because prostate cancer is seen more often in men in this age group (PCFSA, 2013).  
3.4.2 Sampling and Recruitment 
The part of the population selected to take part in the study is known as a sample. The 
researcher utilised convenience sampling, which involves using community members who 
are seen at the study setting during data collection time (Grove et al., 2013). Convenience 
sampling is less expensive, easy, and community members are readily available (Etikan et 
al., 2016). 
A calculated sample size was used. The Raosoft sample size calculator was used to 
calculate the sample size: population was 436; margin of error 5%, confidence level of 95% 
giving a sample size of 183 (n=183). 
The researcher knocked on the doors of houses and invited all men, 40 years and older, to 
be part of the study. Recruitment continued until the sample size (n=183) was realised. 
Community healthcare workers and the community leader accompanied the researcher, 
however, only the researcher collected the data. 
3.4.3 Data collection method and instrument 
This is the process of collecting information, with the intention of addressing the research 
question and achieving the research aim and the purpose (Grove et al., 2013). The 
researcher used structured interviews to collect the data. A questionnaire served as data 
collection instrument. Structured interviews have the advantage of asking the same 
questions to every respondent, questions are standardised, and respondents do not have to 
be literate or able to write to be included in the study (Levashina et al., 2014). 
According to Grove et al. (2013), an instrument utilised by the researcher to write the 
responses of the respondents is called a questionnaire. When using a survey questionnaire, 
data can be collected quickly from a big sample size, it is time efficient and less expensive 
and does not depend on the mood of the researcher. In addition, although the questions are 
easy to design, the information obtained has less depth and the respondents are unable to 
elaborate their answers. 
A questionnaire (Annexure A) containing both open- and closed ended questions was 
developed from the literature (Arafa et al., 2015, Ashford et al., 2001, Arnold-Reed et al., 
2008, Matshela et al., 2014, Paiva et al., 2010), in collaboration with the supervisor, and 
submitted to radiation oncologists  to ensure that the questionnaire was complete and to 
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enhance face- and content validity. The questionnaire was designed to be administered 
verbally to the participant and the responses recorded by the researcher. 
The questionnaire was also pre-tested. Pre-testing is where the instrument is used in a small 
simple size to see if it is user friendly and measures the effectiveness of the questions 
(Grove et al., 2013). The pre-test was conducted on 10% of the eligible respondents in the 
study setting to determine whether the questionnaire was applicable and clear: 
Total population: 183 
Simple size:        10% of 183 
Total:      18 respondents 
The pre-test respondents were not part of the study. No modifications were made to the 
questionnaire because it was found to be clear and applicable.  
The questionnaire consisted of four sections (Annexure A). The first section (A) comprised 
the variables (Table 3.1) and had six questions.  
Table 3.1: The independent variables contained in the questionnaire  
QUESTION VARIABLE GENERAL INFORMATION  
1.  Age   
2.  Cultural group Northern Sotho; Zulu; Xhosa; Tswana; 
others specify:  
3.  Educational levels Never went to school; Grade 1 to7; Grade 8 
to 10; Grade 11 to 12; Tertiary education  
4.  Source of income No income; Self-employed; Employed; 
Government grant; Other 
5.  Income per month No income; Less than R 779.00; More than 
R 779.00 
6.  Preferred healthcare provider 
 
Doctor; Primary healthcare clinic; 
Traditional healer; Spiritual healer; others 
 
The variables for this study are illustrated in Table 3.2. Section two (B) collected information 
on the respondents’ knowledge of prostate cancer. This section consisted of 13 questions. 
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The first question asked was about “having ever heard of prostate cancer”. However, due to 
the risk of giving a socially acceptable answer, the other questions were asked even if the 
respondent answered that he had never heard of prostate cancer.  
Table 3.2: The dependent variable contained in the questionnaire 
Question Focus Dependent variable Characteristics 
1 Awareness  Awareness of prostate 
cancer  
Yes; no; unsure  
 
2 Knowledge  Knowledge of prostate 
cancer  
Cancer in men; cancer that 
spread to other organs if left 
untreated; cancer of the prostate 
gland; do not know 
 
3 Knowledge Anatomical position of 
the prostate 
Beneath the urinary bladder; in 
front the rectum; it surrounds the 
urethra; other; do not know 
4 Knowledge Screening  Men older than 40 years; men 
with family history of prostate; 
men presenting with urinary 
problems; do not know 
5 Knowledge Changes in the body  Urinating frequently especially 
during the night; delayed or 
prolonged urination; weak urine 
stream; incomplete emptying of 
the bladder; pain when passing 
urine; blood in the urine; change 
in bowel habits; new onset of 
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erectile dysfunction; do not 
know; others(specify) 
6 Knowledge  Position about the 
influence on sexual 
functioning 
Yes; no; unsure 
7 Knowledge Influence on sexual 
functioning 
Erectile dysfunction; loss of 
fertility; partner dissatisfaction; 
diminished libido; do not know; 
others(specify) 
8 Knowledge Risks of prostate 
cancer 
Family history of cancer; age; 
consumption; race; other 
(specify) 
9 Knowledge Decreasing the risk of 
developing  prostate 
cancer 
Balanced diet; a low fat diet; 
reduce intake of red meat; 
exercise; screening; others 
(specify) 
10 Knowledge Position about 
prevention  
Yes; no; unsure 
11 Knowledge  Tests done to check 
presence of prostate 
cancer  
Blood test (PSA); digital rectal 
examination (DRE); biopsy; do 
not know; other 
12 Knowledge  Knowledge about 
treatment of prostate 
cancer 
Yes; no; unsure 
 
 
13 Knowledge  Knowledge about 
treatment modalities 
of prostate cancer 
Surgery; radiotherapy, 
chemotherapy; hormone 
therapy; do not know  
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Section three (C) was used to collected information on the attitudes of men regarding 
prostate cancer (Table 3.3). In this section, the focus was on determining how men think 
about prostate cancer and screening methods. 
Table 3.3: The dependent variables contained in the questionnaire  
Question Focus  Dependent variable Characteristics  
1 Attitude The impact of prostate 
cancer as compared to  
HIV/AIDS 
Yes; no; unsure  
2 Attitude Perception about 
consequences of prostate 
cancer  
Yes; no; unsure 
3 Attitude Perception about treatment  Yes; no; unsure 
4 Attitude Perception about screening  Yes; no; unsure 
5 Attitude Position about screening 
only men with urinary 
problem 
Yes; no; unsure  
 
Lastly, Section four (D) collected the information on practices of men regarding prostate 
cancer (Table 3.4).  The section was intended to establish if men had ever experienced 
signs and symptoms of prostate cancer, and if they were prepared to go for screening. 
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Table3.4: The dependent variables contained in the questionnaire  
 
Question Focus Dependent variable  Characteristics 
1 Awareness  Awareness of prostate 
cancer screening  
Yes; no; unsure 
2 Practice  Procedure of prostate 
cancer screening  
Health professional insert gloved 
finger in the anal opening; taking 
blood; taking tissues for 
laboratory analysis; do not know 
3 Practice  Preparation for screening  Yes; no 
4 Practice  Past experience 
concerning prostate cancer 
Urinating frequently especially 
during the night; delayed or 
prolonged urination; weak urine 
stream; incomplete emptying of 
the bladder; pain when passing 
urine; blood in the urine; change 
in bowel habits; new onset of 
erectile dysfunction; do not 
know; others 
5 Practice  History of screening  Yes; no; unsure  
6 practice Healthcare centre for 
screening  
Private doctor; primary health 
care clinic; hospital; other 
7 Practice  Procedure performed: 
Blood test (PSA); digital 
rectal examination 
Yes; no; unsure  
8 Practice  Collection of results  Yes; no; unsure  
30 
 
 
 
3.4.4 Process of data collection 
Data were collected after obtaining ethical clearance from the University of Witwatersrand 
(#M170519) (Annexure B). The researcher notified the Muldersdrift clinic manager and 
community representative about the planned study and obtained their support. During data 
collection, the respondents were visited in their houses. The researcher introduced himself 
and the research topic to the men in a pleasant, positive, informative, culturally sensitive and 
non-aggressive manner. During this meeting, the respondents received an explanation about 
the study’s importance, their value and how much of their time would be required. The 
researcher was unable to ensure privacy due to the social structure of the community. 
A written consent was taken from respondents after the researcher read the information 
letter (Annexure C). It took ± 20 to 30 minutes to complete the questionnaires and adequate 
time was allowed to ensure the questionnaire was completed in full. The data were collected 
from August to September 2017.  
3.4.5 Data management and analysis 
The completed questionnaires were placed in a box and the individual data collected were 
numbered sequentially from 01to183.Data were cleaned and entered onto an Excel 
spreadsheet. Cross tabulation and grouping of the data was performed using statistical 
software STATA version 15.0.According to Grove et al. (2013), computer systems are 
commonly used globally for data analysis and are easy to access and use. Data were also 
analysed in consultation with a statistician.  
Descriptive statistics were used to analyse the data. The description of study variables and 
general characteristics of the sample were summarised using descriptive statistics (Grove et 
al., 2013). Measures of central tendency, for instance mode, median and mean, and 
measures of variability, such as range and standard deviation, and frequency were 
calculated to achieve patterns and trends. The simple Fisher’s Exact Test of independence 
was utilised to see if there was an association between variables. These tests are used 
when researchers want to know whether the proportion of one variable is different among 
values of the other variables. The p-value for this study was set at 0.05 (p=0.05). 
3.5 VALIDITY AND RELIABILITY 
Validity is defined as the extent to which the data collection tool is able to measure what was 
intended to be examined (Grove et al., 2013). More specific, validity is concerned with 
whether the data presents a true picture of what is being studied. However, validity makes 
sure that the results are accurate and well interpreted. The form of validity that can be 
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identified is content validity and face validity. Content validity is defined as the degree to 
which an instrument represents every single element of a construct and adequately covers 
the construct domain (Polit &  Beck, 2012). Content validity ensures the instrument covers all 
the elements of the theoretical contrast. In addition, no specific criteria exist that is used to 
ascertain the content validity of the instrument, however, experts in the specialised area are 
used to examine the content validity of the tool (Polit &  Beck, 2012). 
 
Face validity is defined as the extent to which an instrument appears to measure the 
appropriate variable (Polit &  Beck, 2012). The questionnaire was submitted to experts in the 
field of prostate cancer to ensure it was complete. For accuracy in recording of data, the 
researcher was careful when entering the data into the instrument.     
Reliability is defined as the extent to which a data collection instrument is able to obtain the 
same result when used repeatedly (Lai, 2012).  
3.6 ETHICAL CONSIDERATIONS 
The Health Professions Council of South Africa’s guidelines on ethics (2008) were followed 
in this study. The principles of respect, justice and interest were considered throughout the 
research process (HPCSA, 2008). However, ethics is defined as the appropriateness of 
behaviour in relation to the rights of respondents as demonstrated by the researcher’s work, 
or affected by it (Wilkinson et al., 2012). The ethical principles considered in this study are 
described below. 
3.6.1 Informed consent 
Informed consent is described as the ethical principle used to guide respondents in making 
the decision whether to take part or not in a study (Koutoukidis et al., 2016).The researcher 
ensured that information about the topic and the purpose of the study were made known to 
the respondents. Furthermore, respondents were informed that participation in the study was 
voluntary and they could decline to answer any questions as well as discontinue participation 
without incurring any penalty. The respondents who agreed to take part in the study were 
given a consent form to sign (Annexure D).  
3.6.2 Anonymity and confidentiality 
The researcher ensured that the identity of the respondents and information given were kept 
anonymous, which was achieved by giving respondents code numbers and not indicating 
their names. Research respondents were informed that data collected would be analysed in 
groups and not as individuals. Furthermore, signed consent forms were not attached or 
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stapled to data collection instruments. Lastly, data collected and consent forms were kept 
safe in a well-labelled box. 
3.6.3 Justice 
The principle of justice in research focuses on equal and fair treatment of respondents 
during the study period and equal benefits and burden of the research. Justice was achieved 
through selection of respondents based on the proposed inclusion criteria. It is also 
anticipated that the results might help the healthcare professionals to have an insight of the 
knowledge of men concerning prostate cancer, which will enable them to provide evidence- 
based services to all men. 
3.6.4 Non-maleficence 
The principle of non-maleficence focuses on the protection of research respondents from 
harm. No harm was intended. Interview questions were structured in a polite manner to 
avoid emotional distress. The notion of other people being present could have added to 
distress for the respondent and influenced his answers. 
3.6.5 Ethical approval 
The study was submitted to the University of the Witwatersrand, Human Research Ethics 
Committee (Medical) and written approval was granted (Annexure B).  
3.7 SUMMARY 
This chapter provided details of the research design and method used. The research design, 
setting, population, sampling and recruitment of respondents were elaborated. The data 
collection process, survey questionnaire, data analysis the validity and reliability of the study 
and ethical issues were explained. The next chapter focuses on the results of the study. 
 
 
 
 
 
 
 
33 
 
 
 
CHAPTER 4 
RESULTS AND DISCUSSION 
4.1 INTRODUCTION 
The previous chapter (Chapter 3) provided details of the research design and method used, 
while this chapter describes the results of the study, including general information, 
knowledge, attitudes and practices concerning the disease. 
4.2 GENERAL INFORMATION 
Nearly half (48.1%; n=88) was primarily above the age of 70 years. The mean age was 52.4, 
SD ±9.5 and median 50. Just over a third of respondents were from the Tswana cultural 
group (36.6%; n=67) and the highest percentage never went to school (30.1%; n=55). 
Sources of income varied and the highest percentage of respondents (36.6%; n=67) 
reported no income, 33.3 % (n=61) were employed and 18.0 % (n=33) received a 
government grant. However, close to a half of respondents (58.5%; n=107) lived above the 
South African bread line index of R779.00 per month. When asked which healthcare facility 
they preferred, the majority (73.8%; n=135) indicated primary health clinics. The Muldersdrift 
Primary Health Clinic, which is the nearest to the community, was the only clinic mentioned. 
The general information of the study sample is summarised in Table 4.1. 
Table 4.1: The general information of sample (n=183) 
Age groups n % 
    40-49 13 7.1 
    50-59 30 16.4 
    60-69 52 28.4 
    70+ 88 48.1 
Cultural group 
    Northern Sotho  36 19.7 
    Zulu 37 20.2 
    Xhosa 26 14.2 
    Tswana 67 36.6 
    Other 17 9.3 
Level of education 
    Never went to school 55 30.1 
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    Grade 1-7   52 28.4 
    Grade 8-10 37 20.2 
    Grade 11-12 37 20.2 
    Tertiary education 2 1.1 
Source of personal income 
    No income 67 36.6 
    Self-employed 22 12.0 
    Employed 61 33.3 
    Government grant 33 18.0 
Monthly personal income 
    No income 65 35.5 
    R778.00 and less 11 6.0 
    R779.00 and more 107 58.5 
Preferred healthcare provider 
    Doctor 21 11.5 
    Primary health clinic 135 73.8 
    Traditional healer 16 8.7 
    Spiritual healer 10 5.5 
    Other 1 0.5 
4.3. KNOWLEDGE OF PROSTATE CANCER 
The majority of the respondents (90.2%; n=165) had never heard of prostate cancer and 
only 9.8 % (n=18) had ever heard of the disease. When the respondents were asked to 
explain what they understood about prostate cancer, the majority (92.9%; n=170) reported 
they did not know. Those who provided explanations mentioned “cancer of the private parts” 
(3.3%; n=6), “cancer of the penis” (2.2%; n=4), “cancer of the kidney” (0.5%; n=1), “cancer of 
the testicles” (0.5%; n=1) and “cancer of the urine pipe” (0.5%; n=1). 
When asked about the location of the prostate, the majority of the respondents (90.2%; 
n=165) failed to answer the question. Those who indicated they knew (4.8%; n=9) 
mentioned, “Located in the penis” (2.2%; n=4), in “men’s private parts” (1.1%; n=2), “in the 
testicles” (0.5%; n=1), “below the stomach” (0.5%; n=1) and “in the kidney” (0.5%; n=1). 
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The majority of the respondents (99.5%; n=182) indicated they did not know the function of 
prostate, however, 0.5% (n=1) indicated the prostate “helps with ejaculation” (Table 4.2). 
Table 4.2: Knowledge of men regarding understanding, function, location of prostate 
and prostate cancer (n=183) 
Variable  n % 
Heard of prostate cancer   
    Yes 18 9.8 
    No 165 90.2 
    Unsure 0 0 
Understanding of prostate cancer  
    No answer 170 92.9 
    Cancer for the private parts 6 3.3 
    Cancer of the penis 4 2.2 
    Cancer of the kidney 1 0.5 
    Cancer of the testicles 1 0.5 
    Cancer of the urine pipe 1 0.5 
Location of prostate  
    No answer 173 94.5 
    Located in the penis 4 2.2 
    Located in man’s private parts  2 1.1 
    Located in the testicles 1 0.5 
    Located below the stomach 1 0.5 
    Located in the kidney 2 1.1 
Function of prostate  
    No answer 182 99.5 
    Helps with ejaculation 1 0.5 
 
4.3.1 Association between educational level and age group and had heard of prostate 
cancer 
When cross tabulating ‘had ever heard of prostate cancer’ and educational level and age, it 
was found that the highest percentage of the men who indicated ‘ever heard of this disease’ 
(38.9%; n=7), were within the Grade 11 to 12group. In addition, most of the respondents in 
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the age group 40 to 49 (72.2%; n=13) indicated they ‘had ever heard about prostate cancer.’ 
However, the Fisher’s Exact Test found no statistically significant differences between ‘had 
ever heard of prostate cancer’ and educational level (p=0.418) and age (p=0.249) (Table 
4.3).  
Knowledge of location and function of the prostate was low across all educational levels and 
age groups. Although 4.9% (n=9)answered the question about location and 0.5% (n=1) 
answered the question about the function of the prostate, only one respondent, who was in 
the age group 40 to 49, gave a correct answer by stating it helps with ejaculation.  
Table 4.3 Association between educational level and age group and ‘heard of prostate 
cancer’ (n=183) 
Variable Heard of prostate cancer P-value 
 Yes (n=18) No (n=165)  
Educational status n % n %  
 
0.418 
Never went to school 4 22.2 51 30.9 
Grade 1 to 7 4 22.2 48 29.1 
Grade 8 to 10 3 16.7 34 20.6 
Grade 11 to 12 7 38.9 30 18.2 
Tertiary 0 0.0 2 1.1 
Age group  
40-49 13 72.2 75 45.5  
0.249 50-59 3 16.7 49 29.7 
60-69 2 11.2 28 17.0 
70+ 0 0.0 13 7.9 
 
4.3.2 Knowledge of screening, symptoms and the influence of prostate cancer on 
sexual functioning 
When asked ‘who should be screened for prostate cancer,’ (no list of answers were 
provided) the highest percentage of respondents (46.5%; n=85) reported men presenting 
with urinary problems, 42.6% (n=7) did not know, 6.0% (n=11) indicated men with a family 
history of prostate cancer and 4.9% (n=9) answered men older than 40 years. 
When asked to ‘identify the symptoms of prostate cancer,’ more than half (57.4%; n=105) 
indicated they did not know, however, 45.9% (n=84) were able to identify all seven 
symptoms presented. New onset of erectile dysfunction was the most known symptom 
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(13.7%; n=25), whilst the incomplete emptying of the bladder was the least known (1.1%; 
n=2). 
When asked whether respondents thought prostate cancer could ‘influence a man’s sexual 
functioning,’ the majority (62.3%; n=114) agreed, 20.8% (n=38) reported that prostate cancer 
had no influence on a man’s sexual functioning, whilst 16.9% (n=31) were not sure. When 
asked how prostate cancer could ‘influence sexual functioning,’ half of the respondents 
(50.8%; n=93) indicated it could cause erectile dysfunction, 32.8% (n=60) answered that 
they did not know what the disease could cause, while 19.7% (n=36) indicated that prostate 
cancer could lead to partner dissatisfaction. Less than one third of the respondents (18.0%; 
n=33) indicated that prostate cancer could lead to loss of fertility, while 12.6% (n=23) 
indicated it could lead to diminished libido (Table 4.4). 
Table 4.4 Knowledge of screening, symptoms of prostate cancer and the influence of 
prostate cancer on sexual functioning (n=183)* 
Variable n % 
Who should be screened for prostate cancer   
    Men older than 40 years  9 4.9 
    Men with a family history of prostate cancer 11 6.0 
    Men presenting with urinary problems 85 46.5 
    Do not know 76 42.6 
Symptoms of prostate cancer 
    Urinating frequently especially during the night 9 4.9 
    Delayed or prolonged urination 9 4.9 
    Weak urine stream 15 8.2 
    Incomplete emptying of the bladder 2 1.1 
    Pain when passing urine 8 4.4 
    Blood in the urine  16 8.7 
    New onset of erectile dysfunction 25 13.7 
    Do not know 105 57.4 
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Influence of prostate cancer on sexual functioning (if any) 
    Yes  114 62.3 
    No  38 20.8 
    Unsure  31 16.9 
How prostate cancer influences sexual functioning 
    Erectile dysfunction 93 50.8 
    Loss of fertility 33 18.0 
    Partner dissatisfaction 36 19.7 
    Diminished libido 23 12.6 
    Unsure  60 32.8 
    Other  1 0.5 
* More than one answer was allowed 
4.3.3 Association between educational level, age group, who should be screened, 
symptoms and influence of prostate cancer on sexual functioning. 
When cross tabulating ‘who should be screened for prostate cancer’ and educational level 
and age, it was found that the highest percentage of respondents who indicated they knew 
which men should be screened (28.6%; n=30) never went to school. In addition, most of the 
respondents in the age group 40 to 49, (58.1%; n=61) gave correct answers by indicating 
men older than 40 years, men with a family history of prostate cancer and men presenting 
with urinary problems. 
However, the Fisher’s Exact Test, found no statistically significant difference between 
educational level and knowledge of men who are supposed to be screened for this disease. 
The association between age groups and knowledge of men who are supposed to be 
screened and symptoms of this disease showed a statistically significance, (p=0.007) and 
(p= 0.032) respectively. Once again there was a statistically significant difference between 
educational status and knowledge about the influence of prostate cancer on sexual 
functioning (Fisher’s Exact Test (p=0.001) (Table 4). 
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Table 4.5 Association between educational level, age group, knowledge about who 
should be screened, symptoms and influence of prostate cancer on sexual 
functioning (n=183) 
 Able to identify at least one element of 
screening for prostate cancer 
 
 Yes (n=105) No (n=78)  
Educational status n % n % P-value 
Never went to school 30 28.6 25 32.1 
0.296 
Grade 1 to 7 25 23.8 27 34.6 
Grade 8 to 10 24 22.9 13 16.7 
Grade 11 to 12 24 22.9 13 16.7 
Tertiary 2 2.0 0 0.0 
Age group      
40-49 61 58.1 27 34.6 
0.007* 
50-59 27 25.7 25 32.1 
60-69 13 12.4 17 21.8 
70+ 4 3.8 9 11.5 
 Able to identify at least one prostate cancer 
symptom 
 
 Yes (n=78) No (n=105)  
Educational status n % n %  
Never went to school 30 28.6 25 32.0 
0.296 
Grade 1 to 7 25 23.8 27 34.6 
Grade 8 to 10 24 22.9 13 16.7 
Grade 11 to 12 24 22.9 13 16.7 
Tertiary 2 1.9 0 0.0 
Age group      
40-49 47 60.3 41 39.0 
0.032* 
50-59 19 24.4 33 31.4 
60-69 8 10.3 22 21.00 
70+ 4 5.1 9 8.6 
 Able to identify atleast one Influence of 
prostate cancer on sexual functioning 
 
 Yes (n=113) No (n=70)  
Educational status n % n %  
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Never went to school 30 54.6 25 45.5 
0.001* 
Grade 1 to 7 24 46.2 28 53.9 
Grade 8 to 10 26 70.3 11 29.7 
Grade 11 to 12 32 86.5 5 13.5 
Tertiary 1 50 1 50 
Age group      
40-49 59 52.2 29 41.4 
0.472 
50-59 31 27.4 21 30.0 
60-69 16 14.2 14 20 
70+ 7 6.2 6 8.6 
 Able to indicate how prostate cancer 
influences sexual function 
 
 Yes (n=113) No (n=70)  
Educational status n % n %  
Never went to school 30 54.6 25 45.5 
0.001* 
Grade 1 to 7 24 46.2 28 53.9 
Grade 8 to 10 26 70.3 11 29.3 
Grade 11 to 12 32 86.5 5 13.5 
Tertiary 1 50.0 1 50.0 
Age group  
40-49 59 52.2 29 41.4 
0.346 
50-59 32 28.3 20 28.6 
60-69 16 14.2 14 20.0 
70+ 6 5.3 7 10 
Key: *= statistical significance 
4.3.4 Knowledge about the risk factors, prevention, diagnostic tests and treatment of 
prostate cancer 
When asking the respondents about the ‘risk factors of prostate cancer,’ the majority (88.5%; 
n=162) indicated they did not know, less than a third (6.0%; n= 11) mentioned family history 
of cancer, whilst 4.4% (n=8) and 1.1% (n=2) mentioned age and race respectively. When 
asked to mention ‘factors minimising the risk of developing this disease,’ the majority 
(86.9%; n=159) indicated they did not know; those who indicated they knew (13.1%; n=24) 
mentioned a balanced diet (5.5%; n=10), exercise (2.2%; n=4), a reduced intake of red meat 
(2.7%; n=5), screening (1.6%; n=3) and only two respondents (1.1%; n=2) mentioned a low 
fat diet. 
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When asked whether ‘prostate cancer can be prevented,’ most of the respondents (42.8%; 
n=78) reported they were not sure, 29.0% (n=53) reported the disease can be prevented, 
whilst almost one third (28.4%; n=52) indicated that prostate cancer cannot be prevented at 
all. The majority of the respondents (76.0%; n=139) stated they were unaware of any 
screening tests for this disease. The blood test and biopsy was mentioned by 16.4% (n=30) 
and 6.6% (n=12) respectively, while 1% (n=2) stated urine tests. The DRE was not 
mentioned at all. 
When asked ‘if prostate cancer can be cured,’ the highest percentage of the respondents 
(45.9%; 84), indicated it was a curable disease, while 36.6% (n=67) indicated they did not 
know and 17.5% (n=32) were not sure. When further asked about ‘curative treatment’ and 
what they ‘considered to be the adequate treatment for early diagnosed prostate cancer,’ 
30.1% (n=55) of the respondents mentioned surgery, 2.2% (n=4) chemotherapy, 1.1% (n=2) 
hormone therapy, 0.5% (n=1) radiotherapy, whilst 66.1% (n=121) did not know (Table 4.6). 
Table 4.6Knowledgeabout risk factors, prevention, diagnostic tests and treatment of 
prostate cancer (n= 183) 
Variable n % 
Risks for prostate cancer  
    Family history of cancer 11 6.o 
    Age  8 4.4 
    Consumption of red meat 0 0 
    Race  2 1.1 
   Other 0 0 
   Unsure  162 88.5 
Factors decreasing risk of developing prostate cancer  
    A balanced diet  10 5.5 
    A low fat diet 2 1.1 
    Reduced intake of red meat 5 2.7 
    Exercise 4 2.2 
    Screening  3 1.6 
    Other  0 0 
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    Do not know  159 86.9 
Prostate cancer is preventable  
   Yes 53 29.0 
    No  52 28.4 
    Unsure 78 42.6 
Tests done to diagnose prostate cancer 
    Blood test (PSA) 30 16.4 
    Digital rectal examination (DRE) 0 0 
    Biopsy  12 6.6 
    Unsure 139 76.0 
    Other 2 1.0 
Prostate cancer can be treated 
   Yes 84 45.9 
    No  67 36.6 
   Unsure 32 17.5 
Treatment of prostate cancer 
    Surgery 55 30.1 
    Radiotherapy  1 0.5 
    Chemotherapy  4 2.2 
    Hormone therapy  2 1.1 
    Do not know  121 66.1 
 
4.3.5 Association between educational level and age groups and risk factors, 
prevention measures, diagnostic tests and treatment. 
When cross tabulating those who were able to identify at least one risk factor for prostate 
cancer and educational level and age group, it was found that the highest percentage 
(28.6%; n=6) who identified the risk factors had never attended school. Most of the 
respondents in the age group 40 to 49 (66.7%; n=14) were able to identify at least one 
factor. Furthermore, when cross tabulating those who were able to identify at least one factor 
which decreases the risk of developing prostate cancer and educational level and age, 
33.3% (n=8) had Grade 11 to 12, and those who were within the age group 40 to 49 (54.2%; 
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n=13) were able to identify atleast one factor decreasing the risk of developing prostate 
cancer. 
However, the Fisher’s Exact Test yielded non-significant results between knowledge of the 
risk factors and educational level, (p = 0.508) and age group (p = 0.328). In addition, there 
were no statistically significant differences between knowledge of factors decreasing the 
development of prostate cancer and educational level status and age group, (p=0.408) and 
(p=0.919) respectively. However, there was statistically significant difference between 
prevention of prostate cancer and educational status, p= 0.046 (Table 4.7). 
Table 4.7 Association between educational level and age group and knowledge about 
risk factors, prevention measures, diagnosing tests and treatment (n=183). 
 
 Able to identify atleast one risk factor for 
prostate cancer 
 
 Yes (n=21) No (n=162)  
Educational status n % n %  
Never went to school 6 28.6 49 30.3 
0.508 
Grade 1 to 7 5 23.8 47 29.0 
Grade 8 to 10 4 19.0 33 20.4 
Grade 11 to 12 5 23.8 32 19.8 
Tertiary 1 4.8 1 0.6 
Age group      
40-49 14 66.7 74 45.7 
0.328 
50-59 3 14.3 49 30.3 
60-69 3 14.3 27 16.7 
70+ 1 4.8 12 7.4 
 Able to identify atleast one factor decreasing 
risk of developing prostate cancer 
 
 Yes (n=24) No (n=159)  
Educational status n % n %  
Never went to school 7 29.2 48 30.2 
0.408 
Grade 1 to 7 4 16.7 48 30.2 
Grade 8 to 10 5 20.8 32 20.1 
Grade 11 to 12 8 33.3 29 18.2 
Tertiary 0 0.0 2 1.3 
Age group      
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40-49 13 54.2 75 47.2 
0.919 
50-59 7 29.2 45 28.3 
60-69 3 12.5 27 17.0 
70+ 1 4.2 12 7.6 
 Able to identify atleast one prevention 
measure of prostate cancer 
 
 Yes (n=53) No (n=130)  
Educational status n % n %  
Never went to school 17 32.1 38 29.2 
0.046* 
Grade 1 to 7 9 17.0 43 33.1 
Grade 8 to 10 11 20.7 26 20.0 
Grade 11 to 12 14 26.4 23 17.7 
Tertiary 2 3.8 0 0.0 
Age group  
40-49 25 47.2 63 48.5 
0.323 
50-59 17 32.1 35 26.9 
60-69 10 18.9 20 15.4 
70+ 1 1.9 12 9.2 
 Able to identify atleast one test done to 
diagnose prostate cancer 
 
 Yes (n=43) No (n=140)  
Educational status n % n %  
Never went to school 13 30.2 42 30.0 
0.198 
Grade 1 to 7 7 16.7 45 32.1 
Grade 8 to 10 10 23.8 27 19.3 
Grade 11 to 12 12 28.6 25 17.9 
Tertiary 1 2.4 1 0.7 
Age group     
40-49 23 54.7 65 46.4 
0.729 
50-59 11 25.6 41 29.3 
60-69 7 16.7 23 16.4 
70+ 2 4.8 11 7.9 
 Able to identify atleast one treatment method 
of prostate cancer 
 
 Yes (n=84) No (n=99)  
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Educational status n % n %  
Never went to school 27 32.1 28 28.3 
0.206 
Grade 1 to 7 17 20.2 35 35.3 
Grade 8 to 10 20 23.8 17 17.2 
Grade 11 to 12 19 22.6 18 18.2 
Tertiary 1 1.2 1 1.0 
Age group      
40-49 39 46.4 49 49.5 
0.862 
50-59 26 30.9 26 26.3 
60-69 14 16.7 16 16.2 
70+ 5 5.9 8 8.1 
Key: *= statistical significance  
4.3.6 Summary of knowledge scores 
The number of correct answers in the knowledge section was 38.When calculating 
respondents’ marks for the correct answers, a total mark between 30 and 38 (80-100%) was 
considered good, between19 and 29 (50-79%) average, and between 0 and 18 (0-49%) 
poor.  All respondents (n=183) scored between 0 and 49%, while no respondent scored 
between 50 to 79%or 80% and more (Table 4.8). 
Table 4.8 Summary of knowledge scores (n=183) 
Total score  n % 
Between 0 and 49 % 183 100 
Between 50 to 79 % 0 0 
80 % and more  0 0 
Total  183 100 
4.4 ATTITUDES REGARDING PROSTATE CANCER 
The majority of the respondents (66.1%; n=121) agreed that prostate cancer was a 
‘dangerous illness, like HIV/AIDS.’ However, 29.5% (n=54) thought prostate cancer was not 
dangerous and 4.4% (n=8) said they were not sure. The majority (83.6%; n=153) agreed that 
prostate cancer ‘could kill a man’, whilst 10.4% (n=19) mentioned prostate cancer ‘could not 
kill a man’ and 6.0% (n=11) were not sure 
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When asked if prostate cancer ‘could be treated,’ half of the respondents (50.3%; n=92) 
stated it could be treated, 36.1% (n=66) disagreed whilst 13.7% (n=25) were not sure. When 
the respondents were asked whether they thought ‘all men above 40 years should go for 
prostate cancer screening,’ 47.5% (n= 87) agreed, 14.2% (n=26) disagreed and 38.3% 
(n=70) were not sure. 
When asked whether ‘only men with urinary problems should go for screening,’ half of the 
respondents (50.8%; n=93) agreed, 32.8% (n=60) mentioned that not only men with urinary 
problems should go for screening, whilst 16.4% (n=30) were not sure. When asked ‘if it is 
important to go for screening at least every 5 years,’ 46.4% (n=85) answered it was 
important, 17.5% (n=32) stated it was not important, whilst 36.6% (n=66) were not sure. The 
attitudes of men concerning prostate cancer were illustrated in Table 4.9. 
Table 4.9: Attitudes towards prostate cancer (n=183) 
Variable  n % 
Prostate cancer is a dangerous illness like  HIV/AIDS 
    Yes  121 66.1 
    No  54 29.5 
    Unsure  8 4.4 
Prostate cancer can kill a man  
    Yes  153 83.6 
    No  19 10.4 
    Unsure  11 6.0 
Prostate cancer  can be treated 
    Yes  92 50.3 
    No  66 36.1 
    Unsure  25 13.7 
 
 
 
Men above 40 years should go for screening  
    Yes  87 47.5 
    No  26 14.2 
    Unsure  70 38.3 
Only men with urinary problems should go for screening  
    Yes  93 50.8 
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    No  60 32.8 
    Unsure  30 16.4 
It is important to go for screening at least every 5 years  
    Yes  85 46.4 
    No  32 17.5 
    Unsure  66 36.1 
 
4.4.1 Association between attitude and educational level and age groups of 
respondents 
The total number of correct answers in the attitude section was six, therefore respondents 
who scored less than three were considered as having a negative attitude while those who 
scored between three and six were regarded as having a positive attitude toward prostate 
cancer. The majority of the respondents (72.0%; n=132) had a positive attitude towards 
prostate cancer.  
It was primarily respondents who never went to school who had a negative attitude towards 
prostate cancer (34.9%; n=19), followed by the age group 70+ (53.9%; n=7), however, there 
was no statistically significant difference between educational status and attitudes (p=0.632), 
as summarised in Table 4.10.  
Table 4.10 Association between attitude and educational level and age groups(n=183) 
Variable     
Attitude towards 
prostate cancer 
Negative 
(n=51) 
 
Positive (n=132) Total P- value 
n (%) n (%) n  
Educational status   
0.632 
Never went to school 19 34.9 36 65.5 55 
Grade 1 to 7 15 28.9 37 71.2 52 
Grade 8 to 10 9 24.3 28 75.7 37 
Grade 11 to 12 8 21.6 29 78.4 37 
Tertiary  0 0 2 100 2 
Age group 
40-49 23 26.1 65 73.9 88 0.219 
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59 13 25.0 39 75.0 52 
60-69 8 26.7 22 73.3 30 
70+ 7 53.9 6 46.2 13 
 
4.5 PRACTICES REGARDING PROSTATE CANCER AND SCREENING 
When asked about prostate cancer screening, only 3.3% (n=6) of the respondents had 
heard about it whilst the majority (96.7%; n=177) indicated they had never heard about it. 
Those who indicated that they had heard about screening explained the screening as “blood 
collection” (1.6%; n=3) and “doctor or nurse inserting gloved finger in the anus” (0.5%; n=1). 
When asked whether the respondents were willing to ‘have prostate cancer screening,’ the 
majority (78.1%; n=143) indicated they were willing, whilst 21.9% (n=40) stated they were 
not willing to be screened. Reasons such as they “are not sick” and they “are taking 
traditional medicine” were presented. The reasons given by the respondents for being 
‘willing to be screened’ were “to know my status” (7.1%; n=13), “to treat cancer before it 
spreads” (4.4%; n=8), “to prevent cancer” (1.1%; n=2) and “having weak urine stream” 
(0.5%; n=1). 
When asked whether they had ‘experienced prostate cancer symptoms,’ some respondents 
indicated urinating frequently especially during the night (22.4%, n=41). Only a few (19.1%; 
n=35) indicated they did not know whether they had ever experienced any of the symptoms, 
while new onset of erectile dysfunction was mentioned by 13.7% (n=25) and lastly blood in 
the urine (1.1%; n=2). 
When asked whether the men had ‘been screened for the disease in the past,’ a high 
percentage (99.5%; n=182) responded negatively and only 0.5% (n=1) had ever been 
screened; this respondent however indicated he never went back to the healthcare facility for 
the results (Table 4.11). 
Table 4.11 Practices regarding prostate cancer and screening (n=183) 
Variable n % 
Heard about prostate cancer screening 
    Yes  6 3.3 
    No  177 96.7 
    Unsure 0 0 
How screening is done 
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    Blood collection 3 1.6 
    Digital rectal examination (DRE) 1 0.5 
    Do not know 179 97.8 
Prepared to go for prostate screening  
    Yes  143 78.1 
    No  40 21.9 
Reasons for having prostate cancer screening 
    To know status 118 64.5 
    Prostate is a dangerous illness 13 7.1 
    To treat cancer before it spreads  8 4.4 
    To prevent prostate cancer 2 1.1 
    Weak urine stream  1 0.5 
Reasons for not having screening  
    Not sick 19 10.4 
    Feeling fine  19 10.4 
    Take traditional medicine  1 0.5 
    Test not available  1 0.5 
    Old age 1 0.5 
History of prostate cancer symptoms  
    Urinating frequently especially during the night  41 22.4 
    Delayed or prolonged urination 21 11.5 
    Weak urine stream  29 15.8 
    Incomplete emptying of the bladder 14 7.7 
    Pain when passing urine  19 10.4 
    Blood in the urine  2 1.1 
    Change in bowel habits  2 1.1 
    New onset of erectile dysfunction  25 13.7 
    Do not know  35 19.1 
    Other  1 0.5 
Had prostate cancer screening  
    Yes  1 0.5 
    No  182 99.5 
    Unsure  0 0 
Place prostate cancer screening was performed  
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    Private doctor  0 0 
    Primary health  clinic  0 0 
    Hospital  0 0 
    Other  1 0.5 
Procedure performed for prostate cancer screening  
Blood test (PSA) 1 0.5 
Digital rectal examination  0 0.5 
Received prostate cancer screening results  
    Yes  0 0 
     No  1 0.5 
 
4.5.1 Summary of individual scores 
Out of the 10 answers considered to be positive practices, most of the respondents (60.7%; 
n=111) responded positively to two questions only, less than half of the respondents (32.8%; 
n=60) responded positively to one question, whilst one respondent (0.6%; n=1), who 
indicated he had once undergone prostate cancer screening, responded positively to seven 
questions (Table 4.12). 
Table 4.12 Summary of practice scores (n=183) 
Number of positive answers n % 
0 8 4.37 
1 60 32.79 
2 111 60.66 
3 3 1.64 
7 1 0.55 
Total 183 100.00 
 
4.6 DISCUSSION 
The study provided evidence that the respondents had limited knowledge of the disease. Not 
only had 90% not heard of this disease, those who indicated they had heard of prostate 
cancer had no idea what it really was. Unfortunately, the current study is similar with other 
studies conducted in Africa, where researchers also found a lack of knowledge. For 
instance, Kabore et al. (2014), in their study in Burkina Faso, found 62% of the men had 
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never heard of the prostate or prostate cancer, Nakandi et al. (2013), through a study carried 
out in Uganda, found 45.9% of the men were unaware of the existence of prostate cancer, 
Atulomah et al. (2010), through a study carried out in Nigeria, found 60.8% of respondents 
were aware of prostate cancer, while the South African study of Mofolo et al. (2015) found 
only 46% of the men had heard of it. 
The study provided evidence that the respondents did not know where the prostate was 
situated in the body or the function of this organ. In contrast,  the study done by Mofolo et al. 
(2015) indicated good knowledge about the location of the prostate. However, according to 
Mofolo et al. (2015), their positive results could have been due to the Sesotho translated 
questionnaire, which might have had an influence on the respondents concerning the 
location of prostate. 
Knowledge about who should be screened for prostate cancer was also low, as less than 
7.0% of the respondents mentioned men older than 40 years and men with a family history 
of prostate cancer. The only relatively well-known indication for screening was urinary 
problems, as identified by 46.5% of the respondents. Other studies found similar trends. A 
study conducted in Uganda by Nakandi et al. (2013) also found that men were not aware of 
the age when early detection services for this disease commences, as only 15.4% of men 
thought prostate cancer screening should commence at age 40 and above.   
It was interesting to find that age and educational level did not influence knowledge about 
who should be screened for prostate cancer. It would be quite reasonable to expect men 
with a higher educational level and those older to have more knowledge of who should be 
screened, as found in the study by (Kabore et al., 2014). However, this finding is supported 
by study conducted in United States of America by Williams and Sallar (2014), which also 
found no correlation between age and educational level and knowledge about who should 
be screened for prostate cancer.  
Considering the small number of respondents who indicated they had heard of prostate 
cancer, it comes as no surprise that their knowledge about prostate cancer symptoms was 
also low. This finding corresponds with a Nigerian study done by Atulomah et al. (2010), who 
found only 1.5% of their respondents knew the specific symptoms of prostate cancer.  
This study provided evidence that men had a limited knowledge of the disease risk factors 
as more than 85% experienced challenges in identifying any risk factor. The same trend was 
found in the studies of (Nakandi et al., 2013, Kabore et al., 2014) who reported poor 
knowledge of the risk factors, such as consumption of red meat and age. In contrast, 
(Odedina et al., 2009) in a study done in Abeokuta, Nigeria, reported good knowledge of the 
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risks amongst the Black men included in the study. However, it seems as if men living in the 
developed world are more knowledgeable about the risk factors, as Horwood et al. (2014), 
through the study carried out  in the UK, found the majority of respondents believed lifestyle, 
such as diet, smoking and exercise, could impact on the risk of disease. 
Knowledge concerning screening services was equally low, as 76% of the respondents were 
unable to identify any. However, Nakandi et al. (2013) found similar trends and reported that 
nearly half (47.9%) of the men in their study were unaware of methods used to investigate 
for the presence of the prostate cancer. Unlike the current study, where the DRE was not 
mentioned at all, 9.5% of the respondents in Nakandi et al. (2013) mentioned the DRE. 
Similarly, knowledge about prostate cancer treatment was low, as the majority of 
respondents (66.1%) reported they did not know of the treatment for prostate cancer. These 
findings were consistent with findings of Ogunsanya et al. (2017), whose study conducted in 
Austin, Texas, indicated that rural respondents scored significantly lower on their knowledge 
of prostate cancer treatment, which could be explained by their type of settlement, economic 
status and cultural groups.   
What is of great concern is the fact that none of the respondents achieved more than 50% 
for the total knowledge score. Various studies (Mofolo et al., 2015, Kabore et al., 2014, 
Nakandi et al., 2013) support this finding; for instance, the study conducted in Uganda by 
Nakandi et al. (2013) and in Ouagadougou, Burkina Faso, by Kabore et al. (2014) found the 
knowledge of prostate cancer was generally poor.  
It was positive to find that the majority of the respondents (72.0%) showed a positive attitude 
towards prostate cancer and that this positive attitude applied across all educational levels 
and to a lesser extent, all age groups. In addition, the respondents in the current study 
considered prostate cancer screening as an important aspect because half (50.8%) stated 
that men with urinary problems should go for screening. However,  Nakandi et al. (2013), in 
their study, found a negative attitude towards prostate cancer screening by men in the study 
conducted in Uganda, as 77% of men in their study never thought of going for early 
detection services for this disease. Additionally, when exploring the attitude towards prostate 
cancer amongst Brazilian men, Paiva et al. (2010) found that 40.6% of respondents had an 
attitude towards prostate cancer, which showed that men had negative attitudes in their 
study.  
This study found the majority of respondents (66.1%) considered prostate cancer as 
dangerous as HIV/AIDS. However, this finding contrasted with a study done in Uganda by 
Nakandi et al. (2013), which found the majority of respondents never looked at prostate 
cancer as a bad disease like HIV/AIDS, and were only worried about going for HIV testing. 
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The majority of respondents (83.6%) thought prostate cancer could kill a man, even though 
less than half (46.4%) mentioned that it was important to go for screening at least every 5 
years.  This finding confirmed the results of a study in Brazil by Paiva et al. (2010), which 
also found that 40% of respondents considered screening for prostate cancer important. 
It was clear that respondents in the current study did not have positive practices concerning 
prostate cancer, as out of 10 answers considered positive for practices, 60.7% of men 
responded positively to two questions only.  These findings are similar to the Brazilian study, 
which reported only 28.1% of the men had a positive practices (Paiva et al., 2010). 
Furthermore, in this study only one man had been screened for prostate cancer, however 
the study that was carried out in Nigeria found that 79.5% of men had never undergone early 
detection services for prostate cancer (Ogunsanya et al., 2017).   
4.7 SUMMARY  
This chapter described the results of the study. The general information, knowledge, attitude 
and practices regarding prostate cancer were discussed. The next chapter (Chapter 5) will 
present the justifications, limitations, recommendations and conclusions of the study. 
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CHAPTER 5 
JUSTIFICATION, LIMITATIONS, RECOMMENDATIONS AND CONCLUSIONS 
5.1 INTRODUCTION 
Chapter 4 described the results of the study and discussed the general information, 
knowledge, attitudes and practices regarding prostate cancer.  Chapter 5 presents the 
justification, limitations, recommendations and conclusions of the study. 
5.2 JUSTIFICATION 
The aim of the study was to describe the knowledge, attitudes and practices of men living in 
Muldersdrift, South Africa, concerning prostate cancer. Chapter 1 provided the orientation for 
the study, Chapter 2 described the literature pertaining to prostate cancer, Chapter 3 
described the research setting, design and methods used in this study and Chapter 4 
presented the results and a discussion of the results. The researcher can therefore state that 
the aim of the study, to describe the knowledge attitudes and practices of men living in 
Muldersdrift concerning prostate cancer has been achieved. 
5.3 LIMITATIONS 
 
The study has various limitations. The study was conducted within one semi-rural area, 
hence making it difficult to generalise to all men in South Africa. Even though the sample 
was adequate for data analysis, the total number of men in South Africa was not well 
represented.  In addition, a questionnaire was used as data collection instrument, which 
could have led to recall bias and socially desirable answers. In addition, a survey tends to 
reflect relatively superficial knowledge and not deep understanding of the topic investigated. 
Lastly, the presence of others could have also influenced the results. However, the 
researcher believes that the rigorous process followed in this study resulted in the provision 
of authentic baseline data 
5.4 RECOMMENDATIONS 
The researcher wishes to recommend the following: 
 Men in this semi-urban area should be educated about prostate cancer regarding risk 
factors and screening. It is recommended that education be carried out at Muldersdrift 
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Primary Health Clinic since the majority of men indicated they use the clinic to access 
healthcare services.   
 
 The study should be done again in other rural areas of South Africa, so that 
generalisation can be made to the whole population. 
5.5 CONCLUSIONS 
The study provided evidence that the men living in the study setting had limited knowledge 
of prostate cancer. Not only had most never heard of the disease, but knowledge of what 
prostate cancer was, its symptoms and the risk factors were also low. However, men have 
shown a positive attitude towards prostate cancer, since majority was willing to undertake 
prostate cancer screening and learn more about the disease. Furthermore, the study has 
shown that men did not have a positive practice concerning prostate cancer, since most of 
them scored low on the 10 answers considered as positive practices. Only one man in this 
study indicated having been screened, but never went back for results.  Lastly, it is 
recommended that education about prostate cancer be conducted at the local clinic to men, 
to increase knowledge about the disease in the study setting.   
5.6 Summary 
This chapter was a summary of the study. It presented the justification, limitation, 
recommendations and conclusions. 
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ANNEXURE A  
DATA COLLECTION INSTRUMENT  
Date..........................      Participant number................. 
SECTION A: DEMOGRPHIC CHARACTERISTICS OFFICIAL 
USE 
1. How old are you?  Q1= 
2. To Which cultural group do 
you belong? 
Northern Sotho 1 Q2= 
Zulu 2 
Xhosa 3 
Tswana 4 
Others specify 5 
3. What level of education did 
you complete? 
Never went to school 1 Q3= 
Grade 1 to 7 2 
Grade 8 to 10 3 
Grade 11 to 12 4 
Tertiary education 5 
4. What is your personal main 
source of income at the 
moment? 
No income  
 
1 Q4= 
Work for myself 
 
2 
Employed 
 
3 
Government grant 
 
4 
Other 
 
5 
5. If you have a personal 
income, how much is it per 
month? 
R779.00 and less 
 
1 Q5= 
More than R779.00 
 
2 
6. Where would you go if you 
need healthcare? 
Doctor 
 
1 Q6= 
Primary Health Care 
clinic 
2 
Traditional Healer 3 
Spiritual healer 4 
Other (specify) 
 
 
 
 
 
 
 
 
5 
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SECTION B: KNOWLEDGE OF PROSTATE CANCER 
 
 
1. Have you ever heard of prostate 
cancer? 
Yes= 
1 
No= 
2 
Unsure= 
3 
Q1= 
1.1 If yes, what do you understand 
prostate cancer is? 
 
 
 
 
 
 
 
 
 
 
 
 
1.2 If yes, where do you think is 
the prostate is situated in the 
body? 
 
 
 
 
 
 
 
 
 
 
 
 
2. If yes, what do you think is the 
function of the prostate is? 
 
 
 
 
 
 
 
 
 
 
 
 
3. Who do you think 
should be screened for 
prostate cancer? 
(Read options) 
Men 
older 
than 40 
years= 
1 
 
Men with a 
family 
history of 
prostate 
cancer= 
2 
 
Men 
presenting 
with urinary 
problems= 
3 
 
Do not know= 
4 
 
 
 
Q3= 
4. What changes in your body 
would make you think that you 
might have prostate cancer? 
(Do not read answers, only tick 
what respondent says) 
Urinating frequently especially during 
the night 
1 Q4= 
Delayed or prolonged urination  
 
2 
Weak urine stream 
 
3 
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Incomplete emptying of the bladder 
 
4 
Pain when passing urine  
 
5 
Blood in the urine 
 
6 
Change in bowel habits  
New onset of erectile dysfunction 
 
7 
Do not know 
 
8 
Other (specify) 
 
 
 
9 
5. Do you think prostate 
cancer can influence a man’s 
sexual functioning? 
Yes= 1 No=2 Unsure=3  
 
 
 
Q=5 
5.1. If yes how? 
(Do not read answers, only tick 
what respondent says) 
Erectile dysfunction 
 
1 Q5.1= 
Loss of fertility 2 
Partner dissatisfaction 3 
Diminished libido 4 
Do not know 
 
5 
Others(specify) 6 
6. What would increase a 
man’s risk of developing 
prostate cancer? 
(Do not read answers, only tick 
what respondent says) 
Family history of cancer 1 Q6= 
Age 
 
2 
Consumption of red meat 3 
Race 4 
Other (specify) 
 
 
 
 
 
5 
 
Do not know 
6 
7. What would decrease your 
risk of developing prostate 
cancer? 
(Do not read answers, only tick 
what respondent says) 
Balanced diet 
 
1 Q7= 
A low fat diet 
 
2 
Reduce intake of red meat 
 
3 
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Exercise 
 
4 
Screening 
 
5 
Other (specify) 
 
 
 
 
 
6 
Do not know 7 
8. Do you think prostate 
cancer can be prevented 
Yes= 
1 
No= 
2 
Unsure= 
3 
Q 8= 
9. Which tests can be done to 
check for presence of prostate 
cancer? 
(Do not read answers, only 
tick what respondent says) 
Blood test (PSA) 
 
1 Q9= 
Digital Rectal Examination(DRE) 
 
2 
Biopsy 
 
3 
Do not know 
 
4 
Others( Specify) 
 
 
 
 
 
5 
10. Do you think prostate 
cancer can be treated? 
Yes= 1 No= 2 Unsure=3 Q10= 
 
 
11. If yes how? 
(Do not read answers, only 
tick what respondent says) 
Surgery 
 
1 Q11= 
Radiotherapy 
 
2 
Chemotherapy 
 
3 
Hormone therapy 4 
Do not know 
 
5 
SECTION C:  ATTITUDES TOWARDS PROSTATE CANCER 
1. Do you see prostate cancer as a 
dangerous illness, just like HIV/AIDS 
Yes= 1 No=2 Unsure=3 Q1= 
2. Do you think prostate cancer can kill 
a man? 
Yes=1 No=2 Unsure=3 Q2= 
3. Do you think prostate cancer can be 
treated? 
Yes=1 No=2 Unsure=3 Q3= 
4. Do you think all men above 40 
years should go for screening? 
Yes=1 No=2 Unsure=3 Q4= 
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5. Do you think only men with urinary 
problems should go for screening? 
Yes=1 No=2 Unsure=3 Q5= 
6. Do you think it is important to go for 
screening at least every 5 years? 
Yes=1 No=2 Unsure=3 Q=6 
SECTION D: PRACTICES OF MEN REGARDING PROSTATE CANCER AND SCREENING 
1. Have you ever heard about prostate cancer 
screening? 
Yes=1 No=2 Unsure=3 
 
 
 
Q1= 
1.1 If yes, can you please tell me how it is 
done? 
 
 
 
 
 
 
 
 
2.  Would you be prepared to go for prostate 
cancer screening? 
Yes 
 
 
 
Why?  
 
 
 
 
 
 
No 
 
 
Why? 
 
 
 
 
 
 
 
 
 
 
 
3. Have you ever experienced the 
following? 
(Read all possibilities) 
Urinating frequently especially 
during the night 
 
1 
 
 
 
Delayed or prolonged urination 
 
2 Q3= 
Weak urine stream 3 
Incomplete emptying of the 
bladder 
 
4 
Pain when passing urine  
 
5 
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Blood in the urine 
 
6 
Change in bowel habits 
 
7 
New onset of erectile dysfunction 8 
Do not know 
 
9 
Others (Specify) 
 
 
 
 
 
 
 
10 
4. Have you ever had prostate cancer 
screening? 
Yes=1 No=2 Unsure=3 Q4= 
4.1. If yes, where? 
(Do not read answers, only tick 
what respondent says) 
Private Doctor  1 Q4.1= 
 Primary Health Clinic  
2 
Hospital  
3 
Others (Specify) 
 
 
 
 
 
 
 
4 
5. What procedure did you 
have? 
 
 
5.0.Blood test 
 
 
 
 
 
Yes=1 
 
 
No=2 
 
 
Unsure=3 
 
 
Q5= 
 
 
5.1.Digital 
Rectal 
Examination 
 
 
Yes=1 No=2 Unsure=3 Q5.1= 
6. If yes, did you go back to the healthcare facility to receive 
the results? 
 
Yes=1 
 
No=2 
 
Q6= 
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ANNEXURE C 
INFORMATION LETTER 
Good day 
My name is Bontshwanetse Baaitse, I am a second year student at University of the 
Witwatersrand, in the Department of Nursing Education doing a degree of Master of Science 
in Nursing (Oncology and Palliative care). I am hoping to conduct a research project to 
describe the current knowledge, attitudes and practices of men in Muldersdrift regarding 
prostate cancer. It is important for you to understand the aim of the study, risks if any, rights, 
and benefits before taking part in the study. 
 
Aim 
The aim of the study is to describe the knowledge, attitudes and practices of men concerning 
prostate cancer to gather information, which will be able to guide preventive campaigns as 
health professionals and healthcare educators would be able to utilise this information when 
planning such campaigns. 
 
Rights of respondents 
Participation in the study is voluntary and your decision not to participate will not attract any 
penalty or affect your access to healthcare services. 
 
Benefits  
Please note there will be no personal benefits attached to participating in this study, 
however, the information will help the health professionals and healthcare educators in 
planning preventive campaigns. 
 
Risks 
No risks are anticipated in this study, however, should you have any emotional distress 
regarding participation in this study, do not hesitate to inform me and you will be referred to 
Psychiatric nurse, Agnes Huiskamp (contact number: 083 2388084). 
 
Confidentiality 
Information collected during this study, including personal data and research data, will be 
kept strictly confidential. However, the Human Research Ethics Committee (HREC), 
University of the Witwatersrand, and my supervisor might inspect the information. Your 
name will not be on the data collection instrument therefore you will be given a number in 
order to maintain your right to confidentiality and privacy. 
Consent  
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You will be required to give consent in this study, however, it will be taken that you have 
agreed to take part in the study if you agree to sign the consent form. If you have any 
questions about the study, do not hesitate to ask me in person. You should not agree to 
participate in this study unless you are satisfied with the procedures involved. 
 
Reimbursement for the study participation 
This study is voluntary; therefore, you will not be paid for participating in the study. 
 
Ethical approval 
This study has been submitted to the University of the Witwatersrand, Human Research 
Ethics Committee (Medical) and that committee has granted written approval. The study is 
sponsored by the Government of Botswana and partly by the researcher himself. The 
sponsor has no influence in this study, therefore may not bias my action. 
 
Contact details of researcher 
Thank you for taking the time to listen to the information letter. For further information 
regarding the study or your rights as a study respondent, please contact me in the 
Department of Nursing Education or on the following telephone number 076 1555620, or 
email me using the following address,bbontshwanetse@yahoo.com 
Contact details of Human Research Ethics Committee chairperson 
If you would like further information regarding your rights as a research respondent, or have 
complaints regarding this research study, you may contact Prof. Cleaton-Jones, Chairperson 
of the University of the Witwatersrand, Human Research Ethics Committee (HREC), and an 
independent committee established to help protect the rights of research respondents, on 
(011) 717 2301. 
 
 
 
 
 
 
69 
 
 
 
ANNEXURE D 
KNOWLEDGE, ATTITUDES AND PRACTICES OF MEN CONCERNING PROSTATE 
CANCER IN MULDERSDRIFT, SOUTH AFRICA 
 
CONSENT FORM 
 
I       (name), give permission to be included in the study. 
I have read and understood the information sheet and I have been given the opportunity to 
ask questions I might have regarding the procedure and my consent to me being included in 
the study.  
 
 
             
Date       Signature  
 
 
       (Witness) 
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Annexure E 
Gill Smithies 
Proofreading & Language Editing Services 
59, Lewis Drive, Amanzimtoti, 4126, Kwazulu Natal 
Cell: 071 352 5410  E-mail: moramist@vodamail.co.za 
 
Work Certificate 
       
To Prof L. Maree, RN DCUR (Pret) 
Address Wits Dept of Nursing Education 
Date 11/01/2018 
Subject Research Report: KNOWLEDGE, ATTITUDES AND PRACTICES OF MEN 
CONCERNING PROSTATE CANCER IN MULDERSDRIFT, SOUTH AFRICA 
 
Ref LM/GS/054 
 
I, Gill Smithies, certify that I have edited the following for language and 
style, 
Research Report: Knowledge, Attitudes and Practices of men concerning 
Prostate Cancer in Muldersdrift, South Africa, 
to the standard as required by Wits Dept. of Nursing Education. 
 
        Gill Smithies 
        11/01/2018  
            
         
 
71 
 
